Adnan Kastrati

Adnan Kastrati's AcademicInfluence.com Rankings

Adnan Kastrati

Philosophy

#3274

World Rank

#5325

Historical Rank

Logic

#1052

World Rank

#1678

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Adnan Kastrati's Degrees

Doctorate Medicine University of Belgrade

Why Is Adnan Kastrati Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Adnan Kastrati's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2012) (7528)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). (2018) (6316)
2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous (2014) (3302)
2018 ESC/EACTS Guidelines on myocardial revascularization. (2018) (3072)
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. (2008) (2081)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. (2018) (1802)
2018 ESC/EACTS Guidelines on myocardial revascularization. (2018) (1712)
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. (1996) (1687)
2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca (2014) (1551)
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis (2007) (1494)
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. (2007) (1078)
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. (2010) (1061)
Estimated radiation dose associated with cardiac CT angiography. (2009) (992)
[2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018) (913)
A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. (2008) (876)
Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. (2001) (787)
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. (2006) (779)
Radiation Dose Estimates From Cardiac Multislice Computed Tomography in Daily Practice: Impact of Different Scanning Protocols on Effective Dose Estimates (2006) (725)
Predictive factors of restenosis after coronary stent placement. (1997) (686)
[2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.] (2018) (669)
Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial (2005) (667)
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. (2009) (656)
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem (2012) (617)
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement (2010) (593)
MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH PERSISTENT ST-SEGMENT ELEVATION (ENDING) (2009) (590)
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. (2004) (582)
Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. (1998) (554)
Ticagrelor with or without Aspirin in High-Risk Patients after PCI. (2019) (539)
Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. (2005) (537)
Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. (1998) (513)
Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. (2000) (498)
Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. (2005) (482)
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. (2008) (481)
Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. (2003) (480)
Association analyses based on false discovery rate implicate new loci for coronary artery disease (2017) (476)
Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. (2006) (452)
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. (2019) (435)
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. (2008) (428)
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel (2009) (426)
Multi-ethnic genome-wide association study for atrial fibrillation (2018) (425)
Impact of P‐glycoprotein on clopidogrel absorption (2006) (420)
Vessel size and long-term outcome after coronary stent placement. (1998) (416)
Current treatment of in-stent restenosis. (2014) (416)
Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014 (2015) (410)
[Intracoronary Stenting and Angiographic Results Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial]. (2001) (410)
Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial (2001) (408)
Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. (2015) (398)
Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. (2012) (380)
5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. (2010) (378)
A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. (2007) (370)
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. (2015) (368)
Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. (2007) (367)
[2018 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS)]. (2019) (367)
Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. (2000) (361)
Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography (2013) (351)
Restenosis after coronary placement of various stent types. (2001) (348)
A RANDOMIZED COMPARISON OF ANTIPLATELET THERAPY AFTER THE PLACEMENT OF CORONARY ARTERY STENTS (1996) (345)
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. (2008) (344)
Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial (2013) (338)
Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. (2015) (335)
Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. (2005) (333)
Abciximab in Patients With Acute ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading: A Randomized Double-Blind Trial (2009) (323)
Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement (2010) (323)
Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials (2016) (321)
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis (2008) (310)
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. (2016) (309)
Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel (2004) (302)
Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment (2007) (295)
Four‐Year Experience With Palmaz‐Schatz Stenting in Coronary Angioplasty Complicated by Dissection With Threatened or Present Vessel Closure (1994) (293)
Classification of coronary artery bifurcation lesions and treatments: Time for a consensus! (2008) (290)
Inactivating mutations in NPC1L1 and protection from coronary heart disease. (2014) (289)
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. (2015) (288)
Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. (2013) (288)
Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents (2006) (286)
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. (2011) (285)
[2014 ESC/EACTS Guidelines on myocardial revascularization]. (2014) (281)
Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. (2011) (278)
Prognostic value of coronary computed tomographic angiography for prediction of cardiac events in patients with suspected coronary artery disease. (2009) (258)
Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. (2007) (252)
Pharmacokinetics of clopidogrel after administration of a high loading dose (2004) (251)
Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis (2015) (249)
Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. (2013) (241)
Influence of lesion length on restenosis after coronary stent placement. (1999) (236)
Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease. (2006) (234)
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. (2009) (232)
Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. (2009) (232)
Standardized imaging for aortic annular sizing: implications for transcatheter valve selection. (2013) (220)
Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. (2006) (220)
Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (2012) (219)
Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy (2004) (215)
Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. (2000) (212)
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. (2010) (212)
A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. (2008) (209)
Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. (2010) (209)
Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease (2017) (204)
2014 ESC/EACTS guidelines on myocardial revascularization. (2015) (202)
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. (2011) (198)
Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. (2008) (197)
Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting. (2000) (195)
Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. (2009) (193)
Intracoronary stenting and risk for major adverse cardiac events during the first month. (1998) (190)
2014 ESC/EACTS guidelines on myocardial revascularization. (2015) (190)
Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. (2001) (187)
2018 ESC/EACTS Guidelines on myocardial revascularization. (2019) (186)
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis (2014) (184)
Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen Loss (2006) (184)
Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. (2009) (182)
Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. (2002) (182)
Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. (2007) (180)
Randomized, Double-Blind, Placebo-Controlled Trial of Oral Sirolimus for Restenosis Prevention in Patients With In-Stent Restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) Trial (2004) (180)
Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. (2015) (180)
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. (2010) (179)
Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. (2006) (178)
Platelets contribute to postnatal occlusion of the ductus arteriosus (2010) (178)
PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. (1999) (174)
Improved noninvasive assessment of coronary artery bypass grafts with 64-slice computed tomographic angiography in an unselected patient population. (2007) (172)
A Randomized Trial Comparing Stenting With Balloon Angioplasty in Small Vessels in Patients With Symptomatic Coronary Artery Disease (2000) (171)
Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial (2011) (170)
Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. (2011) (168)
Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting More Than 12 Hours From Symptom Onset: A Randomized Controlled Trial (2005) (168)
Drug-coated balloon therapy in coronary and peripheral artery disease (2014) (168)
Randomized Comparison of a Titanium-Nitride-Oxide–Coated Stent With a Stainless Steel Stent for Coronary Revascularization: The TiNOX Trial (2005) (168)
Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial. (2014) (164)
Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. (2004) (163)
Coronary balloon angioplasty, stents, and scaffolds (2017) (159)
TaqMan Systems for Genotyping of Disease-Related Polymorphisms Present in the Gene Encoding Apolipoprotein E (2002) (159)
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis (2014) (157)
Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. (2011) (154)
Predictive Factors and Impact of No Reflow After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction (2010) (152)
Influence of stent design on 1‐year outcome after coronary stent placement: A randomized comparison of five stent types in 1,147 unselected patients (2000) (150)
Non-invasive coronary computed tomographic angiography for patients with suspected coronary artery disease: the Coronary Angiography by Computed Tomography with the Use of a Submillimeter resolution (CACTUS) trial. (2007) (150)
Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium† (2015) (147)
Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium† (2015) (147)
Sex-based analysis of outcome in patients with acute myocardial infarction treated predominantly with percutaneous coronary intervention. (2002) (147)
Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. (2008) (147)
Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy (2010) (143)
Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. (2008) (141)
Time Course of Restenosis During the First Year After Emergency Coronary Stenting (1993) (140)
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. (2009) (140)
Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. (2005) (138)
Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. (2007) (137)
Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. (2005) (136)
Predictors of Permanent Pacemaker Implantations and New-Onset Conduction Abnormalities With the SAPIEN 3 Balloon-Expandable Transcatheter Heart Valve. (2016) (136)
A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. (2008) (134)
Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials (2013) (134)
High-Speed Rotational Atherectomy Versus Modified Balloons Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions: The Randomized PREPARE-CALC Trial (2018) (133)
Polymer coatings and delayed arterial healing following drug-eluting stent implantation. (2009) (133)
Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis (2017) (133)
Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. (2003) (133)
Therapy-Dependent Influence of Time-to-Treatment Interval on Myocardial Salvage in Patients With Acute Myocardial Infarction Treated With Coronary Artery Stenting or Thrombolysis (2003) (133)
Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. (2012) (132)
Inhibition of Neointima Formation by a Novel Drug-Eluting Stent System That Allows for Dose-Adjustable, Multiple, and On-Site Stent Coating (2005) (131)
Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting (2009) (131)
Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials (2017) (131)
Gender and restenosis after coronary artery stenting. (2003) (131)
Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. (1997) (131)
Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. (2011) (128)
Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. (2000) (127)
Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. (2002) (126)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2017) (124)
Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease: A Meta-Analysis of Randomized Trials (2012) (124)
Erythropoietin in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Randomized, Double-Blind Trial (2010) (123)
Prognostic value of the modified american college of Cardiology/American heart association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. (1999) (123)
2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. (2010) (121)
Early Administration of Reteplase Plus Abciximab vs Abciximab Alone in Patients With Acute Myocardial Infarction Referred for Percutaneous Coronary Intervention (2004) (121)
[2018 ESC/EACTS Guidelines on myocardial revascularization]. (2018) (119)
Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. (2004) (116)
Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. (2005) (112)
Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. (2007) (112)
Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. (2007) (111)
Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial (2002) (110)
Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes (2008) (110)
Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. (1997) (107)
Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. (2004) (107)
P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose (2005) (107)
Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis (2015) (106)
Gender and myocardial salvage after reperfusion treatment in acute myocardial infarction. (2005) (105)
Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness (2006) (105)
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. (2016) (103)
Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes. (2008) (102)
Early Resolution of ST-Segment Elevation Correlates With Myocardial Salvage Assessed by Tc-99m Sestamibi Scintigraphy in Patients With Acute Myocardial Infarction After Mechanical or Thrombolytic Reperfusion Therapy (2002) (101)
Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. (2014) (100)
Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. (2017) (100)
Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction (2004) (99)
Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. (2006) (99)
Prognostic Value of Coronary Computed Tomographic Angiography in Comparison With Calcium Scoring and Clinical Risk Scores (2011) (98)
Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. (2004) (98)
Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. (2015) (98)
Prognostic value of myocardial salvage achieved by reperfusion therapy in patients with acute myocardial infarction. (2004) (97)
Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation (2008) (96)
Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. (2007) (95)
Prospective Evaluation of 18F-Fluorodeoxyglucose Uptake in Postischemic Myocardium by Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging as a Prognostic Marker of Functional Outcome (2016) (95)
Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study) (2019) (95)
Drug-eluting stents for revascularization of infrapopliteal arteries: updated meta-analysis of randomized trials. (2013) (94)
Mutations in the mitochondrial thioredoxin reductase gene TXNRD2 cause dilated cardiomyopathy. (2011) (93)
Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. (2018) (91)
Relation between plasma fibroblast growth factor‐23, serum fetuin‐A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function (2008) (89)
Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. (2005) (89)
Interlesion dependence of the risk for restenosis in patients with coronary stent placement in in multiple lesions. (1998) (89)
Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stent (2009) (89)
Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial (2014) (88)
Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial. (2017) (88)
Gamma-glutamyl transferase and cardiovascular disease. (2016) (88)
Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. (2015) (87)
Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. (2014) (86)
Emergency coronary stenting for dissection during percutaneous transluminal coronary angioplasty: angiographic follow-up after stenting and after repeat angioplasty of the stented segment. (1994) (86)
Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis (2017) (86)
Operator volume and outcome of patients undergoing coronary stent placement. (1998) (86)
A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. (2008) (85)
Prognostic value of uric acid in patients with acute coronary syndromes. (2012) (84)
Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial. (2015) (83)
Influence of balloon pressure during stent placement in native coronary arteries on early and late angiographic and clinical outcome: A randomized evaluation of high-pressure inflation. (1999) (82)
Multicenter Comparison of Novel Self-Expanding Versus Balloon-Expandable Transcatheter Heart Valves. (2017) (81)
Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. (2010) (80)
High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. (2016) (79)
ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. (2010) (79)
HPA-1 and HPA-3 Polymorphisms of the Platelet Fibrinogen Receptor and Coronary Artery Disease and Myocardial Infarction (2000) (77)
Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial (2001) (77)
Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. (2003) (76)
Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. (2004) (75)
Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials. (2016) (74)
Functional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus (2017) (74)
Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. (2015) (73)
ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. (2009) (73)
Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coronary syndromes. (2008) (72)
Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment (2010) (72)
PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. (2000) (71)
Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. (2006) (71)
Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease: Results From the ISAR-TEST 4 Randomized Trial (2019) (70)
Bimodal distribution of angiographic measures of restenosis six months after coronary stent placement. (1997) (70)
Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. (2005) (70)
Tissue Characterization After Drug-Eluting Stent Implantation Using Optical Coherence Tomography (2013) (69)
Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis. (2003) (69)
Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions (2007) (69)
Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. (2013) (69)
Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. (2002) (68)
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Patients With Chronic Stable Angina (2005) (68)
Circulating homocysteine levels in patients with type 2 diabetes mellitus. (2008) (67)
A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. (2004) (66)
Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. (2011) (66)
Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. (2004) (66)
Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. (2020) (66)
Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: A randomized double‐blind controlled trial (2005) (66)
Mechanical reperfusion and long-term mortality in patients with acute myocardial infarction presenting 12 to 48 hours from onset of symptoms. (2009) (65)
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. (2020) (65)
Clinical and angiographic follow‐up after balloon angioplasty with provisional stenting for coronary in‐stent restenosis (1999) (65)
A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy. (2004) (65)
Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. (2005) (64)
Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. (2000) (64)
Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. (2010) (64)
Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. (2008) (64)
Association of Transforming Growth Factor-&bgr;1 Gene Polymorphisms With Myocardial Infarction in Patients With Angiographically Proven Coronary Heart Disease (2006) (64)
Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. (2010) (63)
High platelet reactivity and clinical outcome – Fact and fiction (2011) (63)
A randomized trial comparing phosphorylcholine‐coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries (2004) (62)
Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis (2005) (62)
Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. (2013) (62)
Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. (2011) (61)
Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary (2018) (59)
A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. (2010) (59)
Cytochrome P 450 2 C 19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention (2009) (59)
Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. (2001) (59)
Clopidogrel therapy in patients undergoing coronary stenting: Value of a high‐loading‐dose regimen (2002) (58)
Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures: Evidence From a Hierarchical Bayesian Network Meta-Analysis of 124 Trials and 28 240 Patients (2017) (58)
The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. (2009) (58)
Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients (2017) (58)
Prognostic Value of Access and Non–Access Sites Bleeding After Percutaneous Coronary Intervention (2013) (57)
Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. (2016) (57)
Everolimus-Eluting Versus Sirolimus-Eluting Stents: A Meta-Analysis of Randomized Trials (2011) (57)
A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction. (2004) (57)
Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction. (2006) (56)
One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. (2008) (56)
Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. (2011) (56)
No Replication of Association Between Estrogen Receptor &agr; Gene Polymorphisms and Susceptibility to Myocardial Infarction in a Large Sample of Patients of European Descent (2005) (56)
Statin treatment following coronary artery stenting and one-year survival. (2002) (56)
Tumor necrosis factor-α, lymphotoxin-α, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting (2003) (56)
Association of uric acid with mortality in patients with stable coronary artery disease. (2012) (56)
Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging. (2012) (56)
High-sensitivity troponin T level and angiographic severity of coronary artery disease. (2011) (55)
Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. (2008) (54)
Fluoroscopy-guided aortic root imaging for TAVR: "follow the right cusp" rule. (2013) (54)
Comparative in‐vitro validation of eight first- and second‐generation quantitative coronary angiography systems (1997) (53)
Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. (2016) (53)
Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. (2001) (52)
Overexpansion of the SAPIEN 3 Transcatheter Heart Valve: A Feasibility Study. (2015) (52)
Drug-eluting stents for diabetes mellitus: a rush to judgment? (2005) (51)
Outcomes After Transcatheter Aortic Valve Replacement Using a Novel Balloon-Expandable Transcatheter Heart Valve: A Single-Center Experience. (2015) (51)
Five‐year clinical outcomes of a polymer‐free sirolimus‐eluting stent versus a permanent polymer paclitaxel‐eluting stent: Final results of the intracoronary stenting and angiographic restenosis – test equivalence between two drug‐eluting stents (ISAR‐TEST) trial (2013) (51)
A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. (2000) (51)
Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent? (2016) (51)
Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial. (2016) (50)
Efficacy and safety of collagen implants for haemostasis of the vascular access site after coronary balloon angioplasty and coronary stent implantation (1995) (50)
Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. (2008) (50)
Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. (2008) (48)
One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. (2005) (48)
Vascular access and closure in coronary angiography and percutaneous intervention (2013) (48)
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel (2004) (48)
Drug-Eluting Stents in Percutaneous Coronary Intervention (2009) (48)
Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting. (2000) (48)
Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). (2018) (48)
Long-Term Outcomes After MitraClip Implantation According to the Presence or Absence of EVEREST Inclusion Criteria. (2017) (47)
Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials (2012) (47)
ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. (2008) (47)
ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. (2008) (47)
Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus (2007) (47)
Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. (2015) (46)
CD14 gene -159C/T polymorphism is not associated with coronary artery disease and myocardial infarction. (2002) (46)
Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction (2009) (46)
No Association of ABCB1 C3435T Genotype With Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting (2012) (46)
Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment. (2003) (45)
Risk of combining PPIs with thienopyridines: fact or fiction? (2009) (45)
State of the art: coronary artery stents - past, present and future. (2017) (45)
Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy. (2013) (45)
Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants (2021) (45)
Platelet function in clopidogrel-treated patients with acute coronary syndrome (2007) (45)
Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STEREO trial. (2003) (45)
Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States. (2014) (45)
Optimal value of filling pressure in the right side of the heart in acute right ventricular infarction. (1990) (44)
Efficacy Over Time With Drug-Eluting Stents in Saphenous Vein Graft Lesions. (2018) (44)
Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany (2021) (44)
Tissue factor promotor polymorphism -603 A/G is associated with myocardial infarction. (2004) (44)
Percutaneous edge‐to‐edge repair of the mitral valve in patients with degenerative versus functional mitral regurgitation (2014) (44)
Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. (2019) (44)
Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. (2013) (43)
Safety and Efficacy of a Potential Treatment Algorithm by Using Manual Compression Repair and Ultrasound-Guided Thrombin Injection for the Management of Iatrogenic Femoral Artery Pseudoaneurysm in a Large Patient Cohort (2014) (43)
Uric acid and prognosis in angiography‐proven coronary artery disease (2013) (43)
Association of coronary atherosclerotic burden with clinical presentation and prognosis in patients with stable and unstable coronary artery disease (2012) (43)
Long-term outcome after coronary stenting (2000) (42)
ABO locus O1 allele and risk of myocardial infarction (2004) (42)
Patterns of Presentation and Outcomes of Patients with Acute Coronary Syndromes (2009) (41)
High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: results from the Primary Coronary Angioplasty Trialist versus thrombolysis (PCAT)-2 collaboration. (2011) (41)
Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease. (2014) (41)
The assessment of area at risk and myocardial salvage after coronary revascularization in acute myocardial infarction: comparison between CMR and SPECT. (2013) (41)
Prognostic value of late gadolinium enhancement in cardiovascular magnetic resonance imaging after acute ST-elevation myocardial infarction in comparison with single-photon emission tomography using Tc99m-Sestamibi. (2014) (41)
Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. (2012) (40)
Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis (2017) (40)
Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with Diabetes mellitus: a patient-level meta-analysis of randomized trials (2011) (40)
Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting. (2007) (40)
Predictors for long‐term survival after transcatheter edge‐to‐edge mitral valve repair (2017) (40)
Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials (2010) (40)
Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison. (2013) (39)
Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients (2010) (39)
A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity (2014) (39)
Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement. (2003) (38)
Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. (2015) (38)
Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. (2007) (38)
ISAR‐PEBIS (Paclitaxel‐Eluting Balloon Versus Conventional Balloon Angioplasty for In‐Stent Restenosis of Superficial Femoral Artery): A Randomized Trial (2017) (38)
Prognostic impact of anemia and iron-deficiency anemia in a contemporary cohort of patients undergoing transcatheter aortic valve implantation. (2017) (38)
Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence. (2008) (38)
Optimal imaging for guiding TAVR: transesophageal or transthoracic echocardiography, or just fluoroscopy? (2015) (37)
Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement (2007) (37)
Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. (2005) (36)
Stem cell mobilization by granulocyte-colony-stimulating factor in acute myocardial infarction: lessons from the REVIVAL-2 trial (2007) (36)
Age-Dependent Effect of Abciximab in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions (2006) (36)
Choice of Contrast Medium in Patients With Impaired Renal Function Undergoing Percutaneous Coronary Intervention (2009) (36)
Randomized Comparison of Paclitaxel-Eluting Balloon and Stenting Versus Plain Balloon Plus Stenting Versus Directional Atherectomy for Femoral Artery Disease (ISAR-STATH) (2017) (35)
Bivalirudin Versus Heparin Plus a Glycoprotein IIb/IIIa Inhibitor in Patients With Non–ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: Pooled Analysis from the ACUITY and ISAR-REACT 4 Trials (2012) (35)
Duration of Dual Antiplatelet Therapy and Long-Term Clinical Outcome After Coronary Drug-Eluting Stent Implantation: Landmark Analyses From the CREDO-Kyoto PCI/CABG Registry Cohort-2 (2012) (35)
Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease. (2013) (35)
Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. (2003) (35)
Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. (2020) (34)
Response to Letter Regarding Article, “Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement” (2010) (34)
Primary intracoronary stenting in acute myocardial infarction: long-term clinical and angiographic follow-up and risk factor analysis. (2000) (34)
Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography (2014) (34)
Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry (2010) (34)
Optical coherence tomography in coronary atherosclerosis assessment and intervention (2022) (34)
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. (2016) (34)
Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial (2018) (34)
N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease. (2006) (34)
Previous cytomegalovirus infection and risk of coronary thrombotic events after stent placement. (2000) (33)
Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. (2016) (33)
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus. (2020) (33)
10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents. (2020) (33)
Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. (2018) (33)
The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions. (2004) (32)
No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population (2007) (32)
A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease. (2013) (32)
Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms. (2006) (32)
No association of chromosome 9p21.3 variation with clinical and angiographic outcomes after placement of drug-eluting stents. (2009) (32)
Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. (2013) (32)
Relationship between residual blood flow in the infarct-related artery and scintigraphic infarct size, myocardial salvage, and functional recovery in patients with acute myocardial infarction. (2005) (32)
G protein beta 3 subunit 825T allele carriage and risk of coronary artery disease. (2003) (32)
Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. (2005) (32)
Alkaline phosphatase and prognosis in patients with coronary artery disease (2017) (31)
Angiographic and clinical outcomes of patients treated with everolimus‐eluting bioresorbable stents in routine clinical practice: Results of the ISAR‐ABSORB registry (2016) (30)
Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality. (2010) (30)
N-terminal pro-brain natriuretic peptide on admission in patients with acute myocardial infarction and correlation with scintigraphic infarct size, efficacy of reperfusion, and prognosis. (2006) (30)
Haplotypes and 5A/6A polymorphism of the matrix metalloproteinase-3 gene in coronary disease: case-control study and a meta-analysis. (2010) (30)
Coronary revascularization in patients with renal insufficiency: restenosis rate and cardiovascular outcomes. (2004) (30)
A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. (2005) (30)
Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials (2008) (30)
Cangrelor - a champion lost in translation? (2009) (30)
Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes (2020) (29)
Assessment of the 9p21.3 locus in severity of coronary artery disease in the presence and absence of type 2 diabetes (2013) (29)
Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. (2007) (29)
A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite (2005) (29)
Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. (2018) (29)
Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. (2011) (28)
Association of variants in the BAT1-NFKBIL1-LTA genomic region with protection against myocardial infarction in Europeans. (2007) (28)
Prevention of restenosis by systemic drug therapy: back to the future? (2005) (28)
Comparison of stenting with balloon angioplasty for lesions of small coronary vessels in patients with diabetes mellitus. (2002) (28)
Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high load (1997) (28)
Prognostic value of kidney function in patients with ST-elevation and non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention. (2009) (28)
Everolimus-Eluting Versus Sirolimus-Eluting StentsClinical Perspective (2011) (28)
Drug-Coated Balloons for Revascularization of Infrapopliteal Arteries: A Meta-Analysis of Randomized Trials. (2016) (27)
Clinical and angiographic outcome after stent placement for chronic coronary occlusion. (1998) (27)
Stenting for small coronary vessels: a contestable winner. (2001) (27)
Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. (2007) (27)
Lumen Segmentation in Intravascular Optical Coherence Tomography Using Backscattering Tracked and Initialized Random Walks (2016) (27)
Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors (2010) (27)
Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention (2014) (27)
Polymorphism of platelet glycoprotein IIb and risk of thrombosis and restenosis after coronary stent placement. (1999) (27)
Drug-eluting stents perform better than bare metal stents in small coronary vessels: a meta-analysis of randomised and observational clinical studies with mid-term follow up. (2012) (27)
Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age (2014) (27)
Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. (2016) (27)
Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB Registry. (2017) (26)
The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry. (2015) (26)
Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. (1999) (26)
Total leucocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention. (2009) (26)
Lower Prevalence of the OCT2 Ser270 Allele in Patients with Essential Hypertension (2006) (26)
The chromosome 9p21 region and myocardial infarction in a European population. (2011) (26)
Predictors of antiplatelet response to prasugrel during maintenance treatment (2015) (26)
Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting. (2004) (26)
Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention (2009) (26)
Acute and Midterm Outcome After MitraClip Therapy in Patients With Severe Mitral Regurgitation and Left Ventricular Dysfunction. (2015) (26)
Neoatherosclerosis in Patients With Coronary Stent Thrombosis: Findings From Optical Coherence Tomography Imaging (A Report of the PRESTIGE Consortium). (2018) (26)
Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. (2009) (25)
Local cyclin‐dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug‐ eluting stents to prevent neointima formation following vascular injury (2004) (25)
G protein beta3 subunit polymorphism and risk of thrombosis and restenosis following coronary stent placement. (2000) (25)
Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. (2001) (25)
One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial (2010) (25)
Conduction Abnormalities and Pacemaker Implantations After SAPIEN 3 Vs SAPIEN XT Prosthesis Aortic Valve Implantation. (2016) (25)
Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI—Design and Rationale of the Randomized ISAR-PLASTER Trial (2019) (25)
Usefulness of intracoronary brachytherapy for in-stent restenosis with a 188Re liquid-filled balloon. (2001) (25)
Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions (2018) (25)
Pharmacological inhibition of coronary restenosis: systemic and local approaches (2014) (24)
Genetically modulated educational attainment and coronary disease risk. (2019) (24)
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction (2014) (24)
Reproducibility of area at risk assessment in acute myocardial infarction by T1- and T2-mapping sequences in cardiac magnetic resonance imaging in comparison to Tc99m-sestamibi SPECT (2014) (24)
Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial. (2021) (24)
ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation (2013) (24)
Covered stents for endovascular repair of iatrogenic injuries of iliac and femoral arteries. (2015) (24)
Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm. (1990) (24)
Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention (2010) (24)
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents (2017) (24)
Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. (2014) (24)
Veno-arterial extracorporeal membrane oxygenation (ECMO) in patients with cardiogenic shock: rationale and design of the randomised, multicentre, open-label EURO SHOCK trial (2021) (23)
4G/5G polymorphism and haplotypes of SERPINE1 in atherosclerotic diseases of coronary arteries (2010) (23)
Transcatheter Aortic and Mitral Valve‐in‐Valve Implantation Using the Edwards Sapien 3 Heart Valve (2018) (23)
P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate‐induced platelet activation and aggregation after administration of a single high dose of clopidogrel (2006) (23)
Haptoglobin gene subtyping by restriction enzyme analysis. (2003) (23)
ST-segment resolution after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. (2012) (23)
Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial (2017) (23)
4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. (2003) (23)
A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. (2011) (23)
Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. (2010) (23)
Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography. (2013) (23)
Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial. (2020) (22)
Three-dimensional transoesophageal echocardiography for the assessment of clip attachment to the leaflets in percutaneous edge-to-edge repair of the mitral valve. (2013) (22)
Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome (NSTE-ACS): a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. (2020) (22)
Abstract 2126: CYP2C19 Genetic Variants and Clinical Outcomes With Clopidogrel: A Collaborative Meta-Analysis (2009) (22)
Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials (2015) (22)
Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration (2017) (22)
Value of serum ferritin and soluble transferrin receptor for prediction of coronary artery disease and its clinical presentations. (2004) (22)
Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomised trials versus other limus-eluting stents and an adjusted indirect comparison (2012) (22)
Drug-eluting stents versus bare-metal stents in diabetic patients with ST-segment elevation acute myocardial infarction: a pooled analysis of individual patient data from seven randomized trials. (2009) (22)
Intra-aortic balloon counterpulsation in patients with acute myocardial infarction without cardiogenic shock. A meta-analysis of randomized trials. (2012) (22)
Gamma-glutamyl transferase and prognosis in patients with coronary artery disease. (2016) (21)
Distribution of angiographic measures of restenosis after drug-eluting stent implantation (2009) (21)
Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. (2018) (21)
Super High-Pressure Balloon versus Scoring Balloon to Prepare Severely Calcified Coronary Lesions: The ISAR-CALC Randomized Trial. (2020) (21)
Five‐year clinical outcomes of sirolimus‐eluting versus paclitaxel‐eluting stents in high‐risk patients (2011) (21)
Emergency extracorporeal membrane oxygenation in transcatheter aortic valve implantation: A two‐center experience of incidence, outcome and temporal trends from 2010 to 2015 (2018) (21)
Prognostic value of uric acid in patients with Type 2 diabetes mellitus and coronary artery disease. (2013) (21)
Lack of support for association between common variation in TNFSF4 and myocardial infarction in a German population (2008) (20)
Parallel suture technique with ProGlide: a novel method for management of vascular access during transcatheter aortic valve implantation (TAVI). (2017) (20)
Genotyping of the angiotensin I-converting enzyme gene insertion/deletion polymorphism by the TaqMan method. (2005) (20)
Standardized methodology for transfemoral transcatheter aortic valve replacement with the Edwards Sapien XT valve under fluoroscopy guidance. (2014) (20)
Outcome after new generation single‐layer polytetrafluoroethylene‐covered stent implantation for the treatment of coronary artery perforation (2018) (20)
Proximal occlusion versus distal filter for cerebral protection during carotid stenting: updated meta-analysis of randomised and observational MRI studies. (2015) (20)
Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials (2015) (20)
Microstructuring of stainless steel implants by electrochemical etching (2006) (20)
Comparison of Prasugrel and Bivalirudin vs Clopidogrel and Heparin in Patients With ST‐Segment Elevation Myocardial Infarction: Design and Rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Trial (2014) (20)
Bioresorbable drug-eluting stents: an immature technology in need of mature application. (2015) (20)
Is diabetes the achilles' heel of limus-eluting stents? (2011) (19)
Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. Intracoronary Stenting and Antithrombotic Regimen. (2001) (19)
Ticagrelor or Prasugrel in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (2020) (19)
Intracoronary stenting and angiographic results: Restenosis after direct stenting versus stenting with predilation in patients with symptomatic coronary artery disease (ISAR‐DIRECT trial) (2004) (19)
Previous Cytomegalovirus Infection and Restenosis After Coronary Stent Placement (2001) (19)
Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. (2018) (19)
Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. (2018) (19)
One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial. (2013) (19)
Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease (2011) (19)
Distal embolic protection in patients with acute myocardial infarction: attractive concept but no evidence of benefit. (2005) (18)
ISAR-REACT 3 A : a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention (18)
Randomized Comparison of Intensified and Standard P2Y12-Receptor-Inhibition Before Elective Percutaneous Coronary Intervention (2020) (18)
Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials) (2015) (18)
New roads, new ruts: lessons from drug-eluting stent restenosis. (2011) (18)
Homocysteine Status and Polymorphisms of Methylenetetrahydrofolate Reductase Are Not Associated With Restenosis After Stenting in Coronary Arteries (2003) (18)
Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials. (2015) (18)
Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. (2011) (18)
A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investigator-Initiated trial. (2016) (18)
Mechanical strategies to enhance myocardial salvage during primary percutaneous coronary intervention in patients with STEMI. (2016) (18)
Angiotensin I-converting enzyme (ACE) inhibitors and restenosis after coronary artery stenting in patients with the DD genotype of the ACE gene. (2003) (18)
Bleeding complications in patients undergoing percutaneous coronary interventions: current status and perspective. (2014) (18)
Comparison of prognostic value of high-sensitivity and conventional troponin T in patients with non-ST-segment elevation acute coronary syndromes. (2011) (18)
Relation of body mass index to bleeding during percutaneous coronary interventions. (2015) (17)
Accuracy of N-terminal pro-brain natriuretic peptide to predict mortality in various subsets of patients with coronary artery disease. (2007) (17)
Endovascular therapy for steno-occlusive subclavian and innominate artery disease. (2015) (17)
Chronic dysfunction of the endothelium is associated with mortality in acute coronary syndrome patients. (2013) (17)
Fibrinogen Genes and Myocardial Infarction: A Haplotype Analysis (2008) (17)
The EURO SHOCK Trial: Design, Aims and Objectives. (2020) (17)
Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting. (2005) (17)
Outcomes of patients treated with ultrathin-strut biodegradable polymer sirolimus-eluting stents versus fluoropolymer-based everolimus-eluting stents: a meta-analysis of randomised trials. (2018) (17)
Pathway Analysis Using Genome-Wide Association Study Data for Coronary Restenosis – A Potential Role for the PARVB Gene (2013) (16)
EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury. (2008) (16)
Second‐versus first‐generation “Limus”‐eluting stents in diabetic patients with coronary artery disease: A randomized comparison in setting of ISAR‐TEST‐4 trial (2013) (16)
Comparative prognostic value of C-reactive protein & fibrinogen in patients with coronary artery disease (2014) (16)
Association of Toll-like receptor 4 polymorphism with age-dependent systolic blood pressure increase in patients with coronary artery disease (2015) (16)
A prospective, non-randomized comparison of SAPIEN XT and CoreValve implantation in two sequential cohorts of patients with severe aortic stenosis. (2014) (16)
Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting (2013) (16)
Effects of G-CSF on systemic inflammation, coagulation and platelet activation in patients with acute myocardial infarction. (2011) (16)
A genome-wide association study identifies a region at chromosome 12 as a potential susceptibility locus for restenosis after percutaneous coronary intervention. (2011) (16)
Comparative analysis of stent placement versus balloon angioplasty in small coronary arteries with long narrowings (the Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries [ISAR-SMART] Trial). (2002) (16)
Pharmacokinetics of clopidogrel in patients with stent thrombosis (2008) (16)
Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis (2016) (16)
Genetic risk factors and restenosis after percutaneous coronary interventions (2000) (16)
Sex differences in the outcome after percutaneous coronary intervention - A propensity matching analysis. (2019) (16)
PlA polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction (2003) (15)
Interleukin 18 gene variation and risk of acute myocardial infarction. (2011) (15)
Will we ever know the optimal duration of dual antiplatelet therapy after drug-eluting stent implantation? (2011) (15)
Antiplatelet therapy after percutaneous coronary intervention. (2022) (15)
Impact of abciximab on mortality and reinfarction in patients with acute ST‐segment elevation myocardial infarction treated with primary stenting (2010) (15)
Association of progression or regression of coronary artery atherosclerosis with long-term prognosis. (2016) (15)
Subphenotyping of Patients With Aortic Stenosis by Unsupervised Agglomerative Clustering of Echocardiographic and Hemodynamic Data. (2021) (15)
Microvascular obstruction in patients with non-ST-elevation myocardial infarction: a contrast-enhanced cardiac magnetic resonance study (2014) (15)
Drug-eluting stents is their future as bright as their past? (2007) (15)
A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel (2013) (15)
Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. (2003) (15)
Drug-coated balloon angioplasty for in-stent restenosis of femoropopliteal arteries: a meta-analysis. (2017) (15)
Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis: A pooled analysis of the Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 3 and 4 (ISAR-DESIRE 3 and (2018) (14)
Assessment of platelet function in whole blood by multiple electrode aggregometry: transport of samples using a pneumatic tube system. (2009) (14)
Relation of Gamma-Glutamyl Transferase to Cardiovascular Events in Patients With Acute Coronary Syndromes. (2016) (14)
Two Rare Variants Explain Association with Acute Myocardial Infarction in an Extended Genomic Region Including the Apolipoprotein(A) Gene (2013) (14)
Reperfusion injury in ST-segment elevation myocardial infarction: the final frontier. (2017) (14)
Monocyte-platelet aggregates affect local inflammation in patients with acute myocardial infarction. (2019) (14)
One year VARC-2-defined clinical outcomes after transcatheter aortic valve implantation with the SAPIEN 3 (2019) (14)
Variations of specific non-candidate genes and risk of myocardial infarction: a replication study. (2011) (14)
Interferon-γ and interferon-γ receptor 1 and 2 gene polymorphisms and restenosis following coronary stenting (2005) (14)
Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies). (2015) (14)
Glycoprotein Ia C807T polymorphism and risk of restenosis following coronary stenting. (2001) (14)
Role of platelet function testing in clinical practice: current concepts and future perspectives. (2011) (14)
Intervention-Based Strategy in Patients With Stable Coronary Artery Disease A Meta-Analysis of 17 Randomized Trials of a Percutaneous Coronary (2011) (14)
Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease. (2006) (14)
Angiographic and clinical outcomes of patients treated with drug-coated balloon angioplasty for in-stent restenosis after coronary bifurcation stenting with a two-stent technique. (2017) (14)
Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor (2012) (14)
Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. (2019) (14)
Sensitive troponin and N‐terminal probrain natriuretic peptide in stable angina (2011) (14)
A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease. (2006) (13)
Inverse association of alanine aminotransferase within normal range with prognosis in patients with coronary artery disease. (2019) (13)
Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel (2006) (13)
Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy. (2014) (13)
Statin pretreatment and presentation patterns in patients with coronary artery disease. (2013) (13)
Association of increased CD8+ and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting (2016) (13)
Angiographic outcomes with biodegradable polymer and permanent polymer drug‐eluting stents (2011) (13)
Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment (2008) (13)
Glycoprotein IIb/IIIa Receptor Inhibition with Abciximab during Percutaneous Coronary Interventions Increases the Risk of Bleeding in Patients with Impaired Renal Function (2008) (13)
A randomized trial comparing the hand‐mounted JoStent with the premounted Multi‐Link Duet stent in patients with coronary artery disease (2001) (13)
Prognostic Value of High-sensitivity Troponin T After Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease. (2016) (13)
Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study (2016) (13)
Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison. (2017) (13)
Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation (2014) (13)
Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial. (2014) (13)
Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis (2012) (13)
Gamma-glutamyl transferase and atrial fibrillation in patients with coronary artery disease. (2017) (13)
A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes (2006) (13)
High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease. (2016) (13)
Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial (2016) (13)
Are we making efficient use of clopidogrel? (2004) (13)
High-sensitivity cardiac troponin T and prognosis in patients with ST-segment elevation myocardial infarction. (2018) (12)
Drug-eluting stent trials: too much non-inferiority, too little progress? (2014) (12)
[Treatment of Paclitaxel-eluting stent restenosis with sirolimus-eluting stent implantation: angiographic and clinical outcomes]. (2008) (12)
Lesions in small coronary vessels disease: should drug-coated balloons replace drug-eluting stents as the treatment of choice? (2011) (12)
Sex-related effectiveness of bivalirudin versus abciximab and heparin in non-ST-segment elevation myocardial infarction. (2013) (12)
Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology (2019) (12)
Intravenous β-blockers in primary percutaneous coronary intervention: new hope for an old therapy. (2013) (12)
Prophylactic ECMO during TAVI in patients with depressed left ventricular ejection fraction (2018) (12)
ORAl iMmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: a patient-level meta-analysis of randomized trials. (2014) (12)
Long lesions, long stents and the long process of stent optimization. (1999) (12)
Alanine aminotransferase—a marker of cardiovascular risk at high and low activity levels (2019) (12)
Subintimal Versus Intraplaque Recanalization of Coronary Chronic Total Occlusions: Mid-Term Angiographic and OCT Findings From the ISAR-OCT-CTO Registry. (2019) (12)
Clinical outcomes by optical characteristics of neointima and treatment modality in patients with coronary in-stent restenosis. (2020) (12)
No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents (2012) (12)
P27 and P53 Gene Polymorphisms and Restenosis following Coronary Implantation of Drug-Eluting Stents (2008) (12)
Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease (2013) (12)
Time-of-day at symptom onset was not associated with infarct size and long-term prognosis in patients with ST-segment elevation myocardial infarction (2019) (12)
Prognostic value of alkaline phosphatase in patients with acute coronary syndromes. (2017) (11)
A pan-coronary artery angiographic study of the association between diabetes mellitus and progression or regression of coronary atherosclerosis (2017) (11)
Hospital admissions with acute coronary syndromes during the COVID-19 pandemic in German cardiac care units (2020) (11)
Apolipoprotein E gene epsilon2/epsilon3/epsilon4 polymorphism and myocardial infarction: case-control study in a large population sample. (2008) (11)
Unmet aspirations--where to now for catheter thrombectomy? (2013) (11)
Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis (2016) (11)
Randomized, Double Blind Trial of 6 Versus 12 Months Of Dual Antiplatelet Therapy After DES-Implantation (ISAR-SAFE) (2014) (11)
Predictors of Need for Permanent Pacemaker Implantation and Conduction Abnormalities With a Novel Self-expanding Transcatheter Heart Valve. (2019) (11)
Prognostic value of thyroid-stimulating hormone within reference range in patients with coronary artery disease. (2015) (11)
Percutaneous coronary intervention: balloons, stents and scaffolds (2018) (11)
Standardized Minimalistic Transfemoral Transcatheter Aortic Valve Replacement (TAVR) Using the SAPIEN 3 Device: Stepwise Description, Feasibility, and Safety from a Large Consecutive Single-Center Single-Operator Cohort (2017) (11)
First use of an expandable sheath and transcaval access for transcatheter Edwards SAPIEN 3 aortic valve implantation. (2015) (11)
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention (2022) (11)
Apolipoprotein E gene ε2/ε3/ε4 polymorphism and myocardial infarction: Case-control study in a large population sample (2008) (10)
Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. (2020) (10)
Myocardial perfusion grade, myocardial salvage indices and long-term mortality in patients with acute myocardial infarction and full restoration of epicardial blood flow after primary percutaneous coronary intervention. (2010) (10)
Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. (2014) (10)
Lack of benefit from nitric oxide synthase inhibition in patients with cardiogenic shock: looking for the reasons. (2007) (10)
Drug-eluting stents versus bare metal stents for the prevention of restenosis in patients with renovascular disease. (2017) (10)
Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo. (2009) (10)
Comparative prognostic value of postprocedural creatine kinase myocardial band and high‐sensitivity troponin T in patients with non‐ST‐segment elevation myocardial infarction undergoing percutaneous coronary intervention (2018) (10)
Estimate of myocardial salvage in late presentation acute myocardial infarction by comparing functional and perfusion abnormalities in predischarge gated SPECT (2008) (10)
One‐year clinical outcome with a novel self‐expanding transcatheter heart valve (2019) (10)
Comparison of Vascular Closure Devices Versus Manual Compression After Femoral Artery Puncture in Women: Gender-Based Analysis of a Large Scale, Randomized Clinical Trial (2018) (10)
Qualitative and quantitative neointimal characterization by optical coherence tomography in patients presenting with in-stent restenosis (2019) (10)
Comparison of Carbohydrate Antigen 125 and N-Terminal Pro-Brain Natriuretic Peptide for Risk Prediction After Transcatheter Aortic Valve Implantation. (2017) (10)
Incidence and predictors of reCurrent restenosis after drug-coated balloon Angioplasty for Restenosis of a drUg-eluting Stent: The ICARUS Cooperation. (2017) (10)
Apolipoprotein E gene polymorphisms and thrombosis and restenosis after coronary artery stenting Published, JLR Papers in Press, October 1, 2004. DOI 10.1194/jlr.M400148-JLR200 (2004) (10)
Questions and answers on workup diagnosis and risk stratification: a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (2020) (10)
A laboratory association between hemoglobin and VerifyNow P2Y12 reaction unit: A systematic review and meta‐analysis (2017) (10)
Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction (2005) (10)
Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study. (2018) (10)
Vascular response to percutaneous coronary intervention with biodegradable-polymer vs. new-generation durable-polymer drug-eluting stents: a meta-analysis of optical coherence tomography imaging trials (2018) (10)
Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents. A pooled analysis of individual patient data from 2 randomized trials. (2019) (9)
Correlates of poor outcome among patients with bleeding after coronary interventions (2014) (9)
Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials (2018) (9)
Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents. (2006) (9)
C-reactive protein and prognosis in women and men with coronary artery disease after percutaneous coronary intervention. (2013) (9)
Efficacy and safety of collagen implants for haemostasis of the vascular access site after coronary balloon angioplasty and coronary stent implantation. A randomized study. (1995) (9)
Bioresorbable Vascular Scaffold Technology Benefits From Healthy Skepticism. (2016) (9)
Obesity-associated hypertension is ameliorated in patients with TLR4 single nucleotide polymorphism (SNP) rs4986790 (2015) (9)
Anatomic guided crossing of a stenotic aortic valve under fluoroscopy: "right cusp rule, part III". (2015) (9)
A proteomic atlas of the neointima identifies novel druggable targets for preventive therapy (2021) (9)
Prognostic value of gamma-glutamyl transferase in patients with diabetes mellitus and coronary artery disease. (2016) (9)
Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. (2009) (9)
Clinical outcomes of patients treated with Nobori biolimus-eluting stent: Meta-analysis of randomized trials. (2014) (9)
Antiplatelet Therapy Discontinuation and the Risk of Serious Cardiovascular Events after Coronary Stenting: Observations from the CREDO-Kyoto Registry Cohort-2 (2015) (9)
Association of interleukin 6 -174 G/C polymorphism with coronary artery disease and circulating IL-6 levels: a systematic review and meta-analysis (2021) (9)
Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European E (2017) (9)
Not all drug-eluting balloons are equally good for patients, not all patients are equally suitable for drug-eluting balloons. (2012) (9)
Multicenter Evaluation of Prosthesis Oversizing of the SAPIEN 3 Transcatheter Heart Valve. Impact on Device Failure and New Pacemaker Implantations. (2019) (9)
Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy (2009) (9)
Is there a preferable DES in diabetic patients? A critical appraisal of the evidence (2008) (9)
Tools and Techniques - Clinical: Fluoroscopic balloon sizing of the aortic annulus before transcatheter aortic valve replacement (TAVR) - follow the "right cusp rule". (2015) (9)
The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders (2011) (9)
Impact of perfusion restoration at epicardial and tissue levels on markers of myocardial necrosis and clinical outcome of patients with acute myocardial infarction. (2011) (9)
Sustained increased risk of adverse cardiac events over 5 years after implantation of gold‐coated coronary stents (2006) (8)
Incidental findings in multislice computed tomography prior to transcatheter aortic valve implantation: frequency, clinical relevance and outcome (2018) (8)
Leucine 7 to Proline 7 Polymorphism of the Preproneuropeptide Y Gene is Not Associated with Restenosis after Coronary Stenting (2003) (8)
Prevalence and Clinical Impact of Iron Deficiency in Patients With Severe Aortic Stenosis Referred for Transcatheter Aortic Valve Implantation. (2019) (8)
Polymer-free sirolimus-eluting versus polymer-based paclitaxel-eluting stents: an individual patient data analysis of randomized trials. (2013) (8)
Reply: Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation. (2015) (8)
Hemodynamic structural valve deterioration following transcatheter aortic valve implantation with latest-generation balloon-expandable valves. (2020) (8)
Serum potassium levels on admission and infarct size in patients with acute myocardial infarction. (2009) (8)
Creatine kinase myocardial band - a biomarker to assess prognostically relevant periprocedural myocardial infarction. (2018) (8)
Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial. (2021) (8)
Increased bleeding risk during percutaneous coronary interventions by arterial hypertension (2016) (8)
Sex-associated differences in clinical outcomes after coronary stenting in patients with diabetes mellitus. (2004) (8)
Expression of CXCR4, VLA-1, LFA-3 and transducer of ERB in G-CSF-mobilised progenitor cells in acute myocardial infarction (2010) (8)
New-generation drug-eluting stents for patients with myocardial infarction. (2012) (8)
New anti-platelet agents: the end of resistance? (2012) (8)
Aggrecan: a new biomarker for acute type A aortic dissection (2021) (8)
Stem cell mobilisation by granulocyte-colony stimulating factor in patients with acute myocardial infarction (2016) (8)
Coronary Stenting after Myocardial Infarction during Twin Pregnancy – A Case Report (2011) (8)
Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease (2021) (8)
Relationship of left ventricular end‐diastolic pressure with extent of myocardial ischemia, myocardial salvage and long‐term outcome in patients with ST‐segment elevation myocardial infarction (2019) (8)
Intravenous Beta Blockers in Primary PCI: New Hope for an Old Therapy (2013) (8)
Rationale and design of a randomised clinical trial comparing vascular closure device and manual compression to achieve haemostasis after diagnostic coronary angiography: the Instrumental Sealing of ARterial puncture site - CLOSURE device versus manual compression (ISAR-CLOSURE) trial. (2014) (8)
Incidence and Predictors of Stent Thrombosis after Endovascular Revascularisation of the Superficial Femoral Artery. (2019) (8)
Area under ROC curve, sensitivity, specificity of N-terminal probrain natriuretic peptide in predicting mortality in various subsets of patients with ischemic heart disease (2007) (7)
Current drug-eluting stents in complex patients and lesions. (2006) (7)
Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion? (2016) (7)
Extended evidence for association between the melanoma inhibitory activity 3 gene and myocardial infarction (2011) (7)
Five‐year follow‐up of polymer‐free sirolimus‐ and probucol‐eluting stents versus new generation zotarolimus‐eluting stents in patients presenting with st‐elevation myocardial infarction (2017) (7)
Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. (2020) (7)
Relation of Ratio of Left Ventricular Ejection Fraction to Left Ventricular End-Diastolic Pressure to Long-Term Prognosis After ST-Segment Elevation Acute Myocardial Infarction. (2019) (7)
Sex and Long-Term Outcomes After Implantation of Absorb Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease. (2019) (7)
Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis. (2019) (7)
Impact of stent size on angiographic and clinical outcomes after implantation of everolimus-eluting bioresorbable scaffolds in daily practice: insights from the ISAR-ABSORB registry. (2016) (7)
Comparison of the FemoSeal Vascular Closure Device With Manual Compression After Femoral Artery Puncture - Post-hoc Analysis of a Large-Scale, Randomized Clinical Trial. (2018) (7)
Evaluation of the Coroflex Theca-Stent for reduction of restenosis (ECORI). (2005) (7)
Is it time to jettison complex mechanical thrombectomy in favor of simple manual aspiration devices? (2010) (7)
Cis-epistasis at the LPA locus and risk of cardiovascular diseases (2021) (7)
Impact of myocardial salvage assessed by (99m)Tc-sestamibi scintigraphy on cardiac autonomic function in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. (2009) (7)
A comparison of gamma-glutamyl transferase and alkaline phosphatase as prognostic markers in patients with coronary heart disease. (2018) (7)
Real clinical experiences of dual versus triple antithrombotic therapy after percutaneous coronary intervention (2018) (7)
720-6 Stenting for Progressive Dissection During PTCA: Clinical, Angiographic and Intravascular Ultrasound Criteria to Define a Low-risk Group not Requiring Subsequent Anticoagulation (1995) (7)
Interferon-gamma and interferon-gamma receptor 1 and 2 gene polymorphisms and restenosis following coronary stenting. (2005) (7)
Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention (2010) (7)
Role of IgG-seropositivity to Chlamydia pneumoniae in early thrombotic events after coronary stent placement. (2003) (7)
The impact of smoking on the antiplatelet action of clopidogrel in non‐ST‐elevation myocardial infarction patients: results from the ISAR‐REACT 4 platelet substudy (2012) (7)
Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort. (2014) (7)
Hybrid PET/MR imaging for the prediction of left ventricular recovery after percutaneous revascularisation of coronary chronic total occlusions (2020) (7)
Prognostic value of glomerular function estimated by Cockcroft-Gault creatinine clearance, MDRD-4, CKD-EPI and European Kidney Function Consortium equations in patients with acute coronary syndromes. (2021) (7)
Accuracy of N-Terminal Probrain Natriuretic Peptide to Predict Mortality or Detect Acute Ischemia in Patients with Coronary Artery Disease (2007) (7)
Prognostic Value of Cardiac Troponin T and Sex in Patients Undergoing Elective Percutaneous Coronary Intervention (2016) (7)
TaqMan assays for genotyping of single nucleotide polymorphisms present at a disease susceptibility locus on chromosome 6 (2005) (7)
Predicting factors for long-term survival in patients with out-of-hospital cardiac arrest – A propensity score-matched analysis (2019) (7)
Iron status and clinical outcome in patients with coronary artery disease after coronary stenting. (2005) (7)
Risk factor analysis for stent occlusion within the first month after successful coronary stent placement (1998) (6)
Outcomes of patients treated with durable polymer platinum-chromium everolimus-eluting stents: a meta-analysis of randomised trials. (2017) (6)
Aspartate aminotransferase and mortality in patients with ischemic heart disease. (2020) (6)
Management of in-stent restenosis. (2022) (6)
Clinical outcomes of complete versus incomplete revascularization in patients treated with coronary artery bypass grafting: insights from the TiCAB trial. (2020) (6)
Lost contact with vessel wall, signed contract with stent thrombosis? (2012) (6)
Duration of antiplatelet therapy following intracoronary stenting: are changes needed? (2008) (6)
Bag of forests for modelling of tissue energy interaction in optical coherence tomography for atherosclerotic plaque susceptibility assessment (2015) (6)
Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. (2018) (6)
Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents (2014) (6)
Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). (2016) (6)
2387Recurrent cardiovascular events and mortality in relation to antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease (MINOCA) (2019) (6)
Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis (2021) (6)
Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. (2019) (6)
Rotational Atherectomy or Balloon-Based Techniques to Prepare Severely Calcified Coronary Lesions. (2022) (6)
Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis. (2017) (6)
Omission of aspirin after ACS or stenting in patients with oral anticoagulation - why have the goalposts moved? (2019) (6)
Aortic Valve Predilatation with a Small Balloon, without Rapid Pacing, prior to Transfemoral Transcatheter Aortic Valve Replacement (2018) (6)
Design and rationale of a randomized trial of COBRA PzF stenting to REDUCE duration of triple therapy (COBRA-REDUCE). (2021) (6)
Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non st-segment elevation myocardial infarction. (2013) (6)
Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial. (2019) (6)
Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial (2011) (6)
The Clinical Impact of Psoas Muscle Cross-Sectional Area on Medium-Term Mortality After Transcatheter Aortic Valve Implantation. (2020) (6)
Hypocholesterolaemia and mortality in patients with coronary artery disease (2019) (5)
Outcomes of rotational atherectomy versus modified balloon angioplasty in severely calcified coronary lesions based on target lesion location: a post hoc analysis of the PREPARE-CALC randomised trial (2020) (5)
Differential Prognostic Value of Galectin-3 According to Carbohydrate Antigen 125 Levels in Transcatheter Aortic Valve Implantation. (2019) (5)
Safety and Efficacy of Ticagrelor Monotherapy According to Drug-Eluting Stent Type: The TWILIGHT-STENT Study. (2021) (5)
The only better alternative to rescue percutaneous coronary intervention is primary percutaneous coronary intervention. (2009) (5)
Disappearing scaffolds, dissolving expectations (2016) (5)
Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial (2011) (5)
Procedure‐related bleeding in elective percutaneous coronary interventions (2015) (5)
SORT OUT V: a new episode in the DES wars (2013) (5)
Pharmacological prevention and management of restenosis (2010) (5)
Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes. (2008) (5)
Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation. (2019) (5)
Long‐term prognostic value of risk scores after drug‐eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISAR‐LEFT‐MAIN and ISAR‐LEFT‐MAIN 2 randomized clinical trials (2017) (5)
Sunday, 26 August 2012 (2012) (5)
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate. (2021) (5)
Transcatheter Valve Repair in Congenitally Corrected Transposition of the Great Arteries. (2021) (5)
Postprocedural high-sensitivity troponin T and prognosis in patients with non-ST-segment elevation myocardial infarction treated with early percutaneous coronary intervention. (2017) (5)
Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. (2022) (5)
Harnessing feature extraction capacities from a pre-trained convolutional neural network (VGG-16) for the unsupervised distinction of aortic outflow velocity profiles in patients with severe aortic stenosis (2022) (4)
Long‐term clinical outcomes after drug eluting stent implantation with and without stent overlap (2021) (4)
ISAR--a story of trials with impact on practice. (2010) (4)
What Treatment Should We Dare in Patients With In-Stent Restenosis? (2018) (4)
Stratification of coronary artery disease patients for revascularization procedure based on estimating adverse effects (2015) (4)
Minimising bleeding during percutaneous coronary intervention (2015) (4)
Endovascular Treatment for Steno-Occlusive Iliac Artery Disease: Safety and Long-Term Outcome (2018) (4)
Hypothermia in patients with acute myocardial infarction: a meta-analysis of randomized trials (2020) (4)
Bifurcation intervention with a two-stent strategy: can one size fit all? (2016) (4)
Association of shock index with short-term and long-term prognosis after ST-segment elevation myocardial infarction. (2019) (4)
Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. (2023) (4)
Impact of target lesion location on procedural and angiographic outcomes of rotational atherectomy versus modified balloon angioplasty prior to drug-eluting stent implantation in severely calcified coronary lesions:a subgroup analysis of the PREPARE-CALC randomized trial. (2019) (4)
PLATELET FUNCTION TESTING GUIDED USE OF PRASUGREL IN PATIENTS WITH HIGH ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY REDUCES THE RISK OF EARLY STENT THROMBOSIS (2012) (4)
Prehospital statin therapy and one-year mortality in patients with stable coronary artery disease undergoing percutaneous coronary intervention. (2013) (4)
ESC Guidelines on the management of acute myocardial infarction with persistent ST-segment elevation (2012) (4)
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI (2022) (4)
Prognostic value of impaired fasting glucose for outcomes of patients with stable angina pectoris treated with percutaneous coronary interventions. (2005) (4)
Markers of Reperfusion and Long-Term (8-Year) Prognosis after Primary Percutaneous Coronary Intervention. (2018) (4)
Ten-Year Follow-Up of Left Main Coronary Artery Revascularization: Still Equipoise Between Percutaneous Interventions and Surgery? (2020) (4)
High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring (2013) (4)
Efficacy of drug‐coated balloon angioplasty in early versus late occurring drug‐eluting stent restenosis: A pooled analysis from the randomized ISAR DESIRE 3 and DESIRE 4 trials (2019) (4)
Need for critical reappraisal of intra-aortic balloon counterpulsation. (2011) (4)
In-Stent Restenosis in the United States: Time to Enrich its Treatment Armamentarium. (2020) (4)
Fluoroscopic calcification‐guided optimal deployment projection during transcatheter aortic valve replacement—“The eye of the pigtail.”(Follow the right cusp rule—Part II) (2016) (4)
Very late scaffold thrombosis after everolimus-eluting bioresorbable scaffold implantation in patients with unremarkable interim surveillance angiography. (2020) (4)
1022-82 A prospective, randomized trial of mild hypothermia during primary percutaneous intervention for acute myocardial infarction (COOL-MI): One-year clinical outcome (2004) (3)
Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents (2016) (3)
Clinical outcome of patients with acute myocardial infarction randomized to either coronary stenting plus abciximab or fibrinolysis plus abciximab (STOPAMI-2 Trial) (2002) (3)
Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual (2009) (3)
PROGNOSTIC VALUE OF MICROVASCULAR OBSTRUCTION ASSESSED BY CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING IN COMPARISON TO TC99M-SESTAMIBI SPECT IN ACUTE MYOCARDIAL INFARCTION (2011) (3)
Guided P2Y12 inhibitor therapy after percutaneous coronary intervention (2021) (3)
Is high pressure inflation necessary for optimal stenting (1998) (3)
Prognosis after revascularization for left main coronary artery disease: insights from the crystal ball. (2015) (3)
Improvement in Risk Stratification in Transcatheter Aortic Valve Implantation Using a Combination of the Tumor Marker CA125 and the Logistic EuroSCORE. (2017) (3)
TCT-207 Extended validation of a decision tool (DAPT score) in patients randomized to 6 or 12 months dual antiplatelet therapy after percutaneous coronary intervention with predominantly second-generation drug-eluting stents. (2016) (3)
Multi-ethnic genome-wide association study for atrial fibrillation (2018) (3)
Cardiogenic Shock: How Long Does the Storm Last? (2016) (3)
Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy (2022) (3)
Valve-in-valve transfemoral TAVR: Sapien 3 valve within a failed core valve bioprosthesis. (2014) (3)
Comparison of latest generation supra-annular and intra-annular self-expanding transcatheter heart valves (2020) (3)
Glycoprotein VI polymorphisms and outcome after percutaneous coronary interventions (2007) (3)
Clinical burden and implications of coronary interventions for in-stent restenosis. (2021) (3)
Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. (2014) (3)
Peroxisome proliferator-activated receptor γ gene polymorphisms and restenosis in diabetic patients after stenting in coronary arteries (2004) (3)
Safety and efficacy of minimalist transcatheter aortic valve implantation using a new-generation balloon-expandable transcatheter heart valve in bicuspid and tricuspid aortic valves (2021) (3)
Ruptured versus stable plaques in human coronary arteries (2011) (3)
Impact of calcified lesion complexity on the success of percutaneous coronary intervention with upfront high-speed rotational atherectomy or modified balloons - A subgroup-analysis from the randomized PREPARE-CALC trial. (2021) (3)
822-1 Oral sirolimus to inhibit-recurrent in-stent stenosis: The randomized, double-blind, placebo-controlled OSIRIS trial (2004) (3)
Monday, 27 August 2012 (2012) (3)
High versus normal balloon pressure dilatation for coronary stent placement. 6-Month clinical and angiographic results from a randomized multicenter trial (1998) (3)
Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease-A meta-analysis of randomized clinical trials. (2019) (3)
Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial (2021) (3)
1463Differential effectiveness of drug-coated balloon vs. drug-eluting stent for bare-metal or drug-eluting stent restenosis: a primary prespecified subanalysis from the DAEDALUS study (2018) (3)
Duration of Dual Antiplatelet Therapy After Drug-eluting Stents Implantation: The Jury Is Still Out. (2015) (3)
Procedural and clinical performance of dual‐ versus single‐catheter strategy for transradial coronary angiography: A meta‐analysis of randomized trials (2020) (3)
Prognostic implications of impaired longitudinal left ventricular systolic function assessed by tissue Doppler imaging prior to transcatheter aortic valve implantation for severe aortic stenosis (2021) (3)
LONG-TERM OUTCOMES OF BIODEGRADABLE POLYMER DRUG-ELUTING STENTS VERSUS DURABLE POLYMER SIROLIMUS-ELUTING STENTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: A POOLED ANALYSIS OF INDIVIDUAL PATIENT DATA FROM THE ISAR-TEST 4 AND LEADERS RANDOMIZED TRIALS (2012) (3)
Long-term follow-up and predictors of target lesion failure after implantation of everolimus-eluting bioresorbable scaffolds in real-world practice. (2020) (3)
Ultrasound-guided thrombin injection for treatment of femoral artery pseudoaneurysm with concomitant AV-fistula - a retrospective single centre experience. (2018) (3)
Correlates and Impact of Coronary Artery Calci ﬁ cations in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (3)
Drug for a while, polymer for life: Is it a good solution? (2008) (3)
Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: a meta-analysis of randomized controlled trials. (2019) (3)
Validation and application of OCT tissue attenuation index for the detection of neointimal foam cells (2020) (2)
Genetic testing to guide therapy? Not for ticagrelor! (2019) (2)
Rebuttal: Comparative prognostic value of postprocedural creatine kinase myocardial band and high‐sensitivity troponin T in patients with non‐ST‐segment elevation myocardial infarction undergoing percutaneous coronary intervention (2018) (2)
Determinants of elevated carbohydrate antigen 125 in patients with severe symptomatic aortic valve stenosis referred for transcatheter aortic valve implantation (2018) (2)
Primary PCI, Late Presenting STEMI, and the Limits of Time. (2021) (2)
Assessing the benefit of vascular closure devices after femoral artery puncture--reply. (2015) (2)
Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization (2016) (2)
TCT-642 Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomized trials versus other limus-eluting stents and an adjusted indirect comparison (2012) (2)
Rotational atherectomy of calcified coronary lesions: current practice and insights from two randomized trials (2022) (2)
The impact of personalized antiplatelet treatment on early adverse events in PCI-treated patients with high on-clopidogrel platelet reactivity: results of the ISAR-HPR registry (2013) (2)
More deserved focus on diabetic patients. (2011) (2)
Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial (2021) (2)
SARS-CoV-2 Infection in Asymptomatic Patients Hospitalized for Cardiac Emergencies: Implications for Patient Management (2020) (2)
Artificial intelligence-enabled phenotyping of patients with severe aortic stenosis: on the recovery of extra-aortic valve cardiac damage after transcatheter aortic valve replacement (2022) (2)
Prognostic Value of De Ritis Ratio with Aspartate Aminotransferase and Alanine Aminotransferase Within the Reference Range. (2022) (2)
Implantation of a MitraClip between two previously implanted MitraClips to treat recurrent severe mitral regurgitation. (2017) (2)
Abstract 28: A Prospective and Randomized Trial to Compare a Left Ventricular Assist Device (Impella LP2.5) With IABP in Patients With Cardiogenic Shock by Acute Myocardial Infarction: The ISAR-SHOCK Trial (2007) (2)
Prognostic value of haemoglobin drop in patients with acute coronary syndromes (2021) (2)
Myocardial Salvage after Reduced-Dose Thrombolysis Combined with Glycoprotein IIb/IIIa Blockade Versus Thrombolysis Alone in Patients with Acute Myocardial Infarction (2004) (2)
Reply to: "Does thrombocytopenia contribute to patent ductus arteriosus?" (2011) (2)
Ten‐Year Clinical Outcomes of Biodegradable Versus Durable Polymer New‐Generation Drug‐Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus (2021) (2)
Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes (2021) (2)
ORAl iMmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: a patient-level meta-analysis of randomized trials (2013) (2)
Abstract 5608: Prognostic Impact of the Baseline White Blood Cell Count in Patients with Acute Myocardial Infarction Undergoing Primary PCI: Results from the HORIZONS-AMI trial (2008) (2)
Stent Optimization Using Optical Coherence Tomography and Its Prognostic Implications After Percutaneous Coronary Intervention (2022) (2)
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention (2021) (2)
TCT-840 Gender Specific Analysis Of The Randomized ISAR-CLOSURE Trial: The Comparison of Vascular Closure Devices Versus Manual Compression After Femoral Artery Puncture (2014) (2)
Ten-year clinical outcomes of drug-eluting stents with different polymer coating strategies by degree of coronary calcification: a pooled analysis of the ISAR-TEST 4 and 5 randomised trials. (2022) (2)
Restenosis in one lesion in patients with multilesion stenting occurs even when the companion lesion is free of restenosis (2001) (2)
Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial. (2021) (2)
Impact of acute myocardial infarct location on myocardial salvage after stenting or thrombolysis (results from the STOPAMI 1 and 2 trials): Stent versus Thrombolysis for Occluded coronary arteries in Patients with Acute Myocardial Infarction. (2003) (2)
Twelve-month clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: insights from the ISAR-REACT 5 trial. (2021) (2)
Outcomes of endovascular treatment for infrapopliteal peripheral artery disease based on the updated TASC II classification (2020) (2)
Activated clotting time during percutaneous coronary intervention: a test for all seasons or a mind tranquilizer? (2015) (2)
1001-8 Long-term results of ISAR-REACT: A randomized trial evaluating Abciximab in patients with elective percutaneous coronary intervention after pretreatment with a high loading dose of clopidogrel (2004) (2)
A patient with angina at night: core curriculum chapters 3 (non-invasive imaging) and 9 (chronic ischaemic heart disease) (2012) (2)
TCT-548 Proximal occlusion versus distal filter for cerebral protection during carotid stenting: a meta-analysis of MRI studies (2014) (2)
Ticagrelor or aspirin after coronary artery bypass in patients with chronic kidney disease. (2021) (2)
Interventional cardiology: Polymer-free drug-eluting stents — a safe and effective option for ACS (2016) (2)
Long‐Term Ticagrelor Versus Prasugrel Pharmacodynamics in Patients With ST‐Segment–Elevation Myocardial Infarction (2020) (2)
Acute haemodynamic effects of nifedipine in patients with ventricular septal defect. (1988) (2)
1106-177 Pharmacokinetics of clopidogrel and its active metabolite in human plasma (2004) (2)
Biodegradable polymer limus-eluting stents are noninferior to permanent polymer-based stents: the ISAR-TEST-4 trial (2010) (2)
Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization (2016) (2)
New aspects in the treatment of acute coronary syndromes without ST-elevation: ICTUS and ISAR-COOL in perspective (2007) (2)
Successful stenting of bilateral multiple renal arteries in a patient with renovascular hypertension. (2007) (2)
Mechanistic insights into the superior clinical efficacy of prasugrel over ticagrelor. (2020) (2)
Cis-epistasis at the LPA locus and risk of coronary artery disease (2019) (2)
Effect of Chronic Kidney Disease in WomenUndergoing Percutaneous CoronaryIntervention With Drug-ElutingStents (2)
Clinical and angiographic outcomes of crossing techniques for coronary chronic total occlusions - The ISAR-CTO Registry. (2021) (2)
Prognostic value of De Ritis ratio in patients with acute myocardial infarction. (2022) (2)
Angiographic and clinical follow-up of patients with asymptomatic restenosis after coronary stent (1998) (2)
Molecular multimodality imaging: has a long-standing dream come true? (2016) (2)
Strengths and Limitations of Real World Data in Patients Treated With Coronary Stents. (2018) (2)
Individualization of dual antiplatelet therapy duration after drug-eluting stent implantation: paradigm and reality. (2013) (2)
Association of midregional proadrenomedullin with coronary artery stenoses, soft atherosclerotic plaques and coronary artery calcium (2012) (2)
Impact of stent strut thickness on arterial healing after drug-eluting stents implantation assessed by optical coherence tomography (2013) (2)
Long-Term Ef fi cacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis 3-Year Results of a Randomized Controlled Trial (2)
Sex differences among patients receiving ticagrelor monotherapy or aspirin after coronary bypass surgery: A prespecified subgroup analysis of the TiCAB trial. (2022) (1)
Stem cell mobilization by granulocyte-colony Stimulating Factor in patients with acute myocardial infarction: five-year results of the REVIVAL-2 trial (2013) (1)
Tissue characterization after DES implantation utilizing optical coherence tomography (2013) (1)
TCT-337 Prognostic value of high-sensitivity cardiac troponin T and gender differences in patients undergoing elective percutaneous coronary intervention. (2016) (1)
Antithrombotic therapy with or without aspirin after percutaneous coronary intervention or acute coronary syndrome in patients taking oral anticoagulation: A meta-analysis and network analysis of randomized controlled trials. (2021) (1)
51 Neointimal tissue coverage and characterization assessment using optical coherence tomography surveillance six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in ISAR-absorb MI trial (2020) (1)
TCT-821 Stem Cell Mobilization by Granulocyte-Colony Stimulating Factor in Patients With Acute Myocardial Infarction: Five-year results of the REVIVAL-2 trial (2013) (1)
Relation of Hypocholesterolemia With Diabetes Mellitus in Patients With Coronary Artery Disease. (2020) (1)
Tuesday, 28 August 2012 (2012) (1)
Improved clinical outcomes with abciximab therapy in acute myocardial infarction: A systematic overview of randomized clinical trials (2003) (1)
Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes. (2021) (1)
ADP-induced platelet aggregation in patients with acute coronary syndrome treated with prasugrel or ticagrelor. Results of the ISAR REACT 5 platelet aggregation substudy (2020) (1)
Abstract 2147: Drug-Eluting Stents Versus Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction: A Pooled Patient-Level Analysis of 7 Randomized Trials. (2007) (1)
Drug‐eluting stents for secondary prevention of restenosis (2004) (1)
Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes (2021) (1)
Immature platelet fraction is a strong predictor of adverse cardiovascular events in patients with acute coronary syndrome. Results of the ISAR-REACT 5 reticulated platelet substudy (2020) (1)
TCT-180 Neointimal Tissue Coverage and Characterization Assessment Using Optical Coherence Tomography Surveillance 6 Months After Implantation of Bioresorbable Scaffolds Versus Conventional Everolimus-Eluting Stents in ISAR-Absorb MI Trial (2019) (1)
TCT-730 A multicenter analysis of incidence and predictors for permanent pacemaker implantations and new conduction abnormalities with a novel self-expandable transcatheter heart valve. (2016) (1)
Reply: Aspirin Treatment and Outcomes After Percutaneous Coronary Intervention: Results of the ISAR-ASPI Registry. (2015) (1)
Glycoprotein IIIa PIA polymorphism and early outcome after coronary stenting in patients with adjunctive abciximab therapy (2003) (1)
TCT-343 Variations in Efficacy and Safety Over Time Between Drug-Coated Balloon and Drug-Eluting Stent for the Treatment of Coronary In-Stent Restenosis: Results from the DAEDALUS Study. (2018) (1)
Neointimal Modi ﬁ cation With Scoring Balloon and Ef ﬁ cacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents A Randomized Controlled Trial (2017) (1)
P5630Morphometric and qualitative differences in neointimal tissue six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in ISAR-Absorb MI trial (2019) (1)
Prediction of risk for bleeding, myocardial infarction and mortality after percutaneous coronary intervention in patients with acute coronary syndromes (2022) (1)
Meta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y12 Inhibitor Thereafter (2021) (1)
Effects of glycoprotein IIb/IIIa blockers. (2007) (1)
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. (2022) (1)
Antithrombotic therapy with or without clopidogrel after transcatheter aortic valve replacement. A meta-analysis of randomized controlled trials (2020) (1)
Anatomic and Flow Characteristics of Left Anterior Descending Coronary Artery Angiographic Stenoses Predisposing to Myocardial Infarction. (2020) (1)
TCT-283 10-Year Clinical Outcomes From a Trial of 3 Limus-Eluting Stents With Different Polymer Coatings in Diabetic Patients With Coronary Artery Disease: Results From the ISAR-TEST 4 Randomized Trial (2019) (1)
Target and non-target vessel related events at 10 years post percutaneous coronary intervention (2022) (1)
Influence of smoking on treatment with clopidogrel. (2012) (1)
TCT-11 Everolimus-Eluting Bioresorbable Scaffolds Versus Drug-Eluting Stents in Patients With Acute Myocardial Infarction: 2-Year Results of the Randomized ISAR-Absorb MI Trial (2019) (1)
EVEROLIMUS-ELUTING (XIENCE V) STENTS VERSUS SIROLIMUS-ELUTING (CYPHER) STENTS IN PATIENTS WITH CORONARY ARTERY DISEASE: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL (2010) (1)
Multivessel percutaneous coronary intervention: a review of the literature and fallacies in its interpretation. (2008) (1)
Abstract 2599: Proteomic Profiling of Plasma Samples in Coronary Artery Disease (2007) (1)
39 Long-term outcomes of a randomized comparison of drug-eluting stents versus bare metal stents in saphenous vein graft lesions – 5-year follow-up of the isar-cabg trial (2017) (1)
The Bayesian Approach and the Results of the ISAR-REACT 5 Trial. (2021) (1)
Angiographic performance of everolimus‐eluting stents for the treatment of coronary in‐stent restenosis in daily practice (2020) (1)
15 Drug-coated balloon angioplasty versus drug-eluting stent implantation for the treatment of bare-metal and drug-eluting stent restenosis: results from the daedalus study (2020) (1)
Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus (2021) (1)
Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus (2021) (1)
High-Sensitivity Cardiac Troponin T in Patients with Severe Chronic Kidney Disease and Suspected Acute Coronary Syndrome (2021) (1)
Clinical safety and efficacy of new-generation single-layer polytetrafluorethylene covered coronary stents. (2023) (1)
Drug-Coated Balloon Versus Plain Balloon€Angioplasty for the Treatment of€Femoropopliteal Artery Disease (1)
Ticagrelor or prasugrel in patients with acute coronary syndrome in relation to glomerular filtration rate (2021) (1)
Clinical guide to the use of antithrombotic drugs in coronary artery disease (2008) (1)
Endovascular therapy of subclavian artery occlusive disease involving the vertebral artery origin. (2020) (1)
Is PlA polymorphism of platelet glycoprotein IIIa associated with acute myocardial infarction (1998) (1)
Is diabetes a leveler of efficacy of DES types? (2010) (1)
Echocardiographic evaluation of left ventricular function using an automated analysis algorithm is feasible for beginners and experts: comparison with invasive and non-invasive methods. (2022) (1)
Research update for articles published in EJCI in 2008 (2010) (1)
Effect of erythropoietin in patients with acute myocardial infarction: two-year results of the REVIVAL-3 trial (2013) (1)
Obesity paradox after percutaneous coronary intervention - closing in on the truth behind the phenomenon. (2020) (1)
SUPPLEMENTAL MATERIAL No Association of ABCB 1 C 3435 T Genotype with Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting (2012) (1)
Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes ‐ A Post‐hoc Analysis of the ISAR‐REACT 5 Trial (2022) (1)
Granulocyte Colony-Stimulating Factor and Acute Myocardial Infarction (2006) (1)
Time does not heal all wounds: very late stent thrombosis eight years after implantation of a sirolimus-eluting stent due to positive remodelling, saccular evaginations and marked vascular inflammation. (2013) (1)
Unusual use of a standard percutaneous transluminal coronary angioplasty balloon catheter to the rescue. (2008) (1)
TCT-409 Optical coherence tomography surveillance of tissue coverage at six months after stenting for acute myocardial infarction with bioabsorbable vascular scaffolds in the ISAR-Absorb MI trial (2017) (1)
Preinterventional levels of C-reactive protein and platelet function in patients with stable angina (2003) (1)
Contemporary drug-eluting stents and companion polymers: durable is not synonymous with harm. (2016) (1)
Coronary Artery Disease Paclitaxel- Versus Sirolimus-Eluting Stents for Unprotected Left Main (2009) (1)
Stent placement in long (≥15 mm) coronary lesions (1998) (1)
Machine learning identifies pathophysiologically and prognostically informative phenotypes among patients with mitral regurgitation undergoing transcatheter edge-to-edge repair. (2023) (1)
Do outcomes following intervention for drug-eluting stent restenosis depend on whether the restenosed stent was polymer-free or polymer-coated? (2020) (1)
Risk factor analysis for the 30-day outcome after coronary stent implantation in patients with acute myocardial infarction (1998) (1)
Association of In‐Hospital Hemoglobin Drop With Decreased Myocardial Salvage and Increased Long‐Term Mortality in Patients With Acute ST‐Segment–Elevation Myocardial Infarction (2022) (1)
P2068Incidence, determinant and temporal impact of definite stent thrombosis on mortality in women: from the WIN-DES collaborative patient-level pooled analysis (2017) (1)
Progress in Drug-Eluting Stent Technology: Have We Come to the End of the Road? (2019) (1)
Diagnosis and management of intramyocardial hematoma after coronary artery perforation: case studies of the Deutsches Herzzentrum München. (2016) (1)
The battle against stent thrombosis—to protect and to serve (2012) (1)
Treatment of coronary drug-eluting stent restenosis: a journey back to the future? (2013) (1)
Drug-Eluting Stent: Weighing Costs and Benefits (2010) (1)
Operator Radiation Exposure During Transradial Coronary Angiography in Obese Patients (2014) (1)
Influence of treatment modality and neointimal characteristics on optical coherence tomography on clinical outcomes of in-stent restenosis (2020) (1)
Structural failure of a coronary stent (2001) (1)
Drug-Eluting Balloons or Stents for Bare-Metal Stent Restenosis. (2016) (1)
TCT-460 Bivalirudin versus heparin during percutaneous coronary intervention: a meta-analysis of randomized trials (2014) (1)
Efficacy of reperfusion with primary percutaneous coronary intervention in patients with acute ST segment elevation myocardial infarction (2011) (1)
Biodegradable-polymer drug-eluting stents: back to the future? (2016) (1)
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk (2022) (1)
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. (2022) (1)
TCT-453 Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. (2016) (1)
Clopidogrel response in patients receiving the nonvitamin K antagonist oral anticoagulants apixaban and rivaroxaban. (2020) (1)
Abstract 4486: Stent Thrombosis After Drug-Eluting Stent Implantation: Incidence, Timing and Relation to Discontinuation of Clopidogrel Therapy Over a 4-Year Period (2008) (1)
Neoatherosclerosis in Patients With Coronary Stent Thrombosis Findings From Optical Coherence Tomography Imaging (A Report of the Consortium) (2018) (1)
INCIDENCE OF PERMANENT PACEMAKER IMPLANTATIONS AND NEW-ONSET INTRAVENTRICULAR CONDUCTION ABNORMALITIES AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: A COMPARISON OF THE NOVEL SAPIEN 3 WITH THE SAPIEN XT PROSTHESIS (2015) (1)
Abstract 3799: Age-Dependent Effect of Abciximab in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions (2006) (1)
Angiographic predictors of unplanned rotational atherectomy in complex calcified coronary artery disease: a pooled analysis from the randomised ROTAXUS and PREPARE-CALC trials. (2021) (1)
TCT-288 Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Intervention: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaborative Patient-Level Pooled Analysis. (2016) (1)
Abstract 1933: Correlates of Bleeding After a 600 mg Loading Dose of Clopidogrel, With and Without Abciximab: A Pooled Analysis of 4 ISAR Randomized Trials. (2007) (1)
Acute coronary artery stent thrombosis following rapid renewal of functional platelets: Implications for intensified antiplatelet therapy (2006) (1)
U-shaped association of central pulse pressure with long-term prognosis after ST-segment elevation myocardial infarction (2019) (1)
Preadmission antiplatelet therapy and treatment effect of ticagrelor versus prasugrel in patients with acute coronary syndromes - a subgroup analysis of the ISAR-REACT 5 trial. (2022) (1)
Long-term clinical impact of polymer-free sirolimus-eluting stents in unselected patients (2016) (1)
ECG-Independent Calculation of Instantaneous Wave-Free Ratio (2017) (1)
P2Y12 inhibitor intensity de-escalation in patients with acute coronary syndromes. (2023) (1)
Periprocedural myocardial injury according to optical characteristics of neointima and treatment modality of in-stent restenosis (2022) (1)
246 Aortic stenosis and valve replacement AORTIC STENOSIS AND VALVE REPLACEMENT P14101 Can 'left ventricular ejection time' still be used as a marker of critical aortic stenosis? (2005) (0)
Response to Aggarwal, Inflammatory response after intervention assesed by serial C-reactive protein measurements correlates with resterosis in patients with coronary stenting (Am Heart J 2005;150:344-50) (2006) (0)
Functional implications of polymorphisms of endothelial nitric oxide synthase gene: Reply (2004) (0)
Antithrombotic therapies for patients with cerebrovascular, peripheral arterial, and coronary artery disease Sahil A Parikh and Joshua A Beckman (2008) (0)
Association of De Ritis Ratio with Prognosis in Patients with Coronary Artery Disease and Aminotransferase Activity within and outside the Healthy Values of Reference Range (2023) (0)
Reply: Drug-Coated Balloons Versus Drug-Eluting Stents for Coronary In-Stent Restenosis. (2020) (0)
TCT-475 Effect of Stent Diameter in Women Undergoing Percutaneous Coronary Intervention with Early- and New-Generation Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. (2016) (0)
Effects of Body Mass Index on ClinicalOutcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (2017) (0)
Abstract 21201: Stent Length Remains an Important Risk for Recurrent Events in Women With or Without Diabetes Mellitus After New Generation DES PCI: From the WIN DES Collaboration (2017) (0)
TCT-414 Two-year outcomes of patients with acute coronary syndrome versus stable coronary disease undergoing bioresorbable scaffold implantation. (2016) (0)
Complete versus Incomplete Revascularization and Influence of Postoperative Antiplatelet Therapy in Coronary Artery Bypass Grafting: Results from the TiCAB Study (2020) (0)
TCT-417 Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis (2017) (0)
Abstract 17312: Amyloid-β (1-40) and the Risk of Death from Cardiovascular Causes in Patients with Coronary Heart Disease (2014) (0)
Response from the authors to: The value of elevated high-sensitivity troponin T (2011) (0)
P2258Prophylactic ECMO for periprocedural support in patients with reduced left ventricular ejection fraction undergoing TAVI (2018) (0)
3122Longterm comparative efficacy of drug-eluting stents versus bare metal stents in saphenous vein graft lesions: 5-year clinical follow-up of a randomized trial (2017) (0)
BIODEGRADABLE POLYMER DRUG-ELUTING STENTS VERSUS DURABLE POLYMER SIROLIMUS-ELUTING STENTS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POOLED ANALYSIS OF INDIVIDUAL PATIENT DATA FROM THE ISAR-TEST 3, ISAR-TEST 4, AND LEADERS RANDOMIZED TRIALS AT 4 YEARS (2012) (0)
Do baseline c-reactive protein levels predict myocardial salvage after reperfusion therapy in patients with acute myocardial infarction? (2003) (0)
CRT-100.35 Long-Term Outcome in Patients With Severely Calcified Stenosis Treated With Intravascular Lithotripsy Compared to Debulking Balloon Angioplasty: A Propensity Score-Adjusted Study (2023) (0)
Granulocyte colony-stimulating factor and acute myocardial infarction. Authors' reply (2006) (0)
Prognostic impact of secondary prevention after coronary artery bypass grafting-insights from the TiCAB trial. (2022) (0)
Clinical and angiographic outcomes following percutaneous treatment of non-occlusive vs. chronically total occluded coronary lesions (2022) (0)
Prognostic value of high-sensitivity cardiac troponin T in patients with stable and unstable coronary artery disease presenting with lowest limit of detection of conventional troponin (2010) (0)
Early outcome of on- versus off-hours admission in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) during COVID-19 pandemic (2023) (0)
648 Drug treatment of acute coronary syndrome patients / Targeting very late restenosis (0)
Duración del tratamiento antiagregante plaquetario combinado doble tras la implantación de stents farmacoactivos: el jurado continúa reunido Duration of Dual Antiplatelet Therapy After Drug-eluting Stents Implantation: The Jury Is Still Out (2016) (0)
TCT-320 Transcatheter Aortic Valve Replacement with the ACURATE NEO – one year results (2017) (0)
Subject Index Vol. 109, 2008 (2007) (0)
TLR4 signaling mediates sbp increase with age–A translational investigation (2014) (0)
How should we treat “undilatable” coronary stents? (2022) (0)
Integrin ß1 polymorphisms and bleeding risk after coronary artery stenting (2019) (0)
TCT-173 Bare-nitinol stent versus paclitaxel-coated balloon for femoro-popliteal revascularization. An adjusted indirect comparison meta-analysis of randomized trials (2012) (0)
ISAR-REACT 4 - Bivalirudin Similar to Abciximab/Heparin in Reducing Ischemic Outcomes in NSTEMI and Has Significantly Less Bleeding (2011) (0)
Looking into the future of ACS patients through the small OCT window. (2022) (0)
urability of Antirestenotic Efficacy n Drug-Eluting Stents With and ithout Permanent Polymer (0)
Ticagrelor or prasugrel in patients with acute coronary syndrome and prior myocardial infarction (2022) (0)
High-speed rotational atherectomy versus modified balloons for plaque preparation of severely calcified coronary lesions: two-year outcomes of the randomised PREPARE-CALC trial. (2022) (0)
Response to the letter to the editor: Mortality risk of elevated alkaline phosphatase in patients with coronary artery disease and percutaneous coronary intervention. (2017) (0)
Meeting Report ESC Forum on Drug Eluting Stents European Heart House, Nice, 27 – 28 2007 (2009) (0)
Evaluation of the new coroflex theca stent for reduction of immune response: The ECORI trial (2004) (0)
TCT-673 Drug-eluting stents versus bare metal stents for saphenous vein graft lesions: meta-analysis of randomized trials (2012) (0)
Meeting Report ESC Forum on Drug Eluting Stents European Heart House, Nice, 27 – 28 2007 (2009) (0)
Association analyses based on false discovery rate implicate 243 susceptibility loci for coronary artery disease (2017) (0)
ISAR-REACT 5 trial: a new guidance for the treatment of acute coronary syndromes (2019) (0)
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock : The TRIUMPH randomized controlled trial. Commentary (2007) (0)
Post market surveillance registry (PIONEER) of the Yukon Choice PC-Elite Coronary Stent System for percutaneous coronary intervention in Indian acute coronary syndrome population (2022) (0)
ASPIRIN TREATMENT AND OUTCOMES AFTER PCI: RESULTS OF THE INTRACORONARY STENTING AND ANTITHROMBOTIC REGIMEN – ASPIRIN AND PLATELET INHIBITION (ISAR-ASPI) REGISTRY (2014) (0)
One-Year Ischemic and Bleeding Events According to Renal Function in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Third-Generation Antiplatelet Drugs. (2022) (0)
Abstract 4310: Impact of Platelet Response to Clopidogrel on Major In-hospital Bleeding Events in Patients Undergoing Coronary Stent Placement (2009) (0)
BleedingandstentthrombosisonP 2 Y 12-inhibitors : collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention (2015) (0)
Infarction in Patients With Angiographically Proven Coronary Heart Disease 1 Gene Polymorphisms With Myocardial β Association of Transforming Growth Factor (2006) (0)
P4559Outcome after single-layer polytetrafluoroethylene-covered stent implantation for the treatment of coronary artery perforation (2018) (0)
Are sirolimus-eluting stents superior to paclitaxel-eluting stents in patients with small-vessel disease? (2008) (0)
Relative Prognostic Utility of Different Bleeding Scales Among Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction: The HORIZONS-AMI Trial (2008) (0)
Don't think twice: BMS is never nice. (2017) (0)
Coronary artery perforation located in a coronary artery bypass graft treated with new-generation single-layer polytetrafluorethylene-covered stent: results from a multicenter Registry. (2022) (0)
Original Article A prospective, non-randomized comparison of SAPIEN XT and CoreValve implantation in two sequential cohorts of patients with severe aortic stenosis (2014) (0)
TCT-842 Drug-eluting stents for revascularization of infrapopliteal arteries. Updated meta-analysis of randomized trials (2013) (0)
Abstract 1675: Effect of Rosiglitazone versus Placebo on Rapid Angiographic Progression of Non-Culprit Coronary Lesions in Patients with Type 2 DM (2007) (0)
TCT-667 Restenosis after coronary stenting in 10,004 patients with follow-up angiography (2012) (0)
1016-53 An Inexpensive, Easy to Use and Highly Portable Quantitative Angiographic System (1995) (0)
Fluoroscopic and tomographic correlation for aortic annulus measurements in transcatheter aortic valve implantation: �follow the right cusp� rule (2023) (0)
Randomized ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions 2: Design and rationale of the ISAR-CALC 2 trial. (2022) (0)
TCT-496 Outcomes After Transcatheter Aortic Valve Replacement with the SAPIEN 3 - the VARC-2 composite endpoints at one year (2018) (0)
Association of a fibrinogen gene haplotype with myocardial infarction (2007) (0)
Contents Vol. 111, 2008 (2008) (0)
Stem Cell Therapy after Acute Myocardial Infarction-The Emperor's New Clothes?: Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor in Patients with Acute Myocardial Infarction: A Randomized Controlled Trial. JAMA 295: 1003-1010, 2006. (2006) (0)
Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. (2020) (0)
Residual Tc-99m sestamibi uptake predicts myocardial salvage in patients undergoing rescue angioplasty after failed thrombolysis in acute myocardial infarction (1999) (0)
Antithrombotic treatment in vein graft interventions Luis A Guzman and Theodore A Bass (2008) (0)
TCT-409 Unsupervised Clustering of Structural and Functional Echocardiographic Parameters Identifies a High-Risk Phenotype Among Patients With Severe Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair (2021) (0)
Stenting of de-novo lesions on unprotected left main coronary artery: Results of a five-year follow-up period (2003) (0)
Haptoglobin Gene Subtyping by Restriction Enzyme (2003) (0)
P3303Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis (2017) (0)
Maladie coronaireSyndrome coronaire aigu : ISAR-REACT 4Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction, A. Kastrati, F.J. Neumann, S. Schultz, et al., in: N Engl J Med, 365 (2011), pp. 1980-1989 (2011) (0)
5704Validation of the SCAI definition of periprocedural myocardial infarction for prediction of one-year mortality following elective percutaneous coronary interventions (2017) (0)
Implant à revêtement multiple (2006) (0)
Molecular multimodality imaging: has a long-standing dream come true? (2016) (0)
Optical coherence tomography tissue coverage and characterization with grey-scale signal intensity analysis after bifurcation stenting with a new generation bioabsorbable polymer drug-eluting stent. (2020) (0)
CRT-100.4 Angiographic Result and Long-Term Outcome in Patients With In-Stent Restenosis Treated With Intravascular Lithotripsy Compared to Debulking Balloon Angioplasty (2023) (0)
MULTICENTER EVALUATION OF PROSTHESIS OVERSIZING FOR THE SAPIEN 3 TRANSCATHETER HEART VALVE – IMPACT ON NEW PACEMAKER IMPLANTATIONS (2017) (0)
Clinical data and treatment in patients with ventricular septal defects without pulmonary hypertension group A ) and with pulmonary hypertension ( group B ) Treatment Age Liver (2005) (0)
Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial (2022) (0)
TCT-181 5-Year Outcomes of Patients Undergoing Everolimus-Eluting Bioresorbable Scaffold Implantation During Daily Clinical Routine: Final Results From the ISAR-Absorb Registry (2019) (0)
Abstract 2127: Protective Effect of the CYP Polymorphism With Increased Activation of Clopidogrel on Cardiovascular Events (2009) (0)
TCT-483 Angiographic and two-year clinical outcomes following percutaneous coronary intervention for in-stent restenosis of polymer-free sirolimus- and probucol-eluting stent compared with durable polymer zotarolimus-eluting stent. (2016) (0)
Ticagrelor With or Without Aspirin in High-Risk Patients With Anemia Undergoing Percutaneous Coronary Intervention: a subgroup analysis of the TWILIGHT trial. (2023) (0)
TCT-591 Stent coverage and neointimal maturity in a randomized trial of limus-eluting stents with biodegradable polymer versus permanent polymer coatings assessed by optical coherence tomography (2013) (0)
Contents Vol. 109, 2008 (2007) (0)
Patent foramen ovale closure for patients excluded from the randomized cryptogenic stroke trials: response to letter by Zaman et al. (2018) (0)
Antithrombotic drugs: oral antiplatelet drugs (2008) (0)
Effect of PCI on quality of life in patients with stable coronary disease, W.S. Weintraub, J.A. Spertus, P. Kolm, in: N Engl J Med, 359. (2008), 677 (2008) (0)
CRT-105 Comparison of Vascular Healing after DES Implantation Utilizing Optical Coherence Tomography and Grey-Scale Signal Intensity Analysis in Atherosclerotic Rabbits, Human Autopsy Specimens and Man (2013) (0)
IMAGING AND DIAGNOSTIC TESTING PROGNOSTIC VALUE OF MICROVASCULAR OBSTRUCTION ASSESSED BY CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING IN COMPARISON TO TC99M-SESTAMIBI SPECT IN ACUTE MYOCARDIAL INFARCTION (2011) (0)
Smoking and restenosis after coronary artery stenting: the artifact of smoker's paradox (2002) (0)
Mechanical Reperfusion More Than 12 Hours After Acute Myocardial Infarction—Reply (2005) (0)
Reduction of thrombus burden: a still unmet need in patients with ST-segment elevation myocardial infarction. (2018) (0)
Macrolide treatment after coronary stent placement (2001) (0)
TCT-58 Long-term clinical outcomes of patients treated with everolimus-eluting bioresorbable scaffolds during daily practice - 2-year results from the ISAR-ABSORB Registry. (2016) (0)
Primary Percutaneous Coronary Intervention: Role of Stenting versus Balloon Angioplasty and Drug-Eluting Stents versus Bare Metal Stents: Trial Evidence and Current Concepts (2010) (0)
Drug-eluting versus bare-metal stents in saphenous vein graft lesions – Author's reply (2012) (0)
Acutehaemodynamic effects ofnifedipine inpatients withventricular septal defect (1988) (0)
Antithrombotic treatment in primary percutaneous coronary intervention (2021) (0)
High Sensitivity Cardiac Troponin T in Patients with Severe Chronic Kidney Disease and suspected Acute Coronary Syn- drome (2021) (0)
TCT-291 3-Year Results of Patients Undergoing Everolimus-eluting Bioresorbable Scaffolds Implantation During Daily Clinical Routine (2017) (0)
Man-machine interaction-based phenotyping identifies pathophysiologically and prognostically informative clusters among patients with mitral regurgitation undergoing transcatheter edge-to-edge repair (2022) (0)
Association of Toll-like receptor 4 polymorphism with age-dependent systolic blood pressure increase in patients with coronary artery disease (2015) (0)
TCT-399 Impact of post-dilatation on angiographic and clinical outcomes of patients undergoing bioresorbable scaffold implantation in clinical practice. (2016) (0)
TCT-228 Outcomes After Treatment of Coronary In-Stent Restenosis With Drug-Coated Balloon Versus Drug-Eluting Stent According to the Presence or Absence of Diabetes Mellitus: A Prespecified Analysis of the DAEDALUS Study. (2018) (0)
Unloading Long Term Effect of Enalapril in Asymptomatic Patients With Severe Chronic Aortic Regurgitation (1998) (0)
878-3 Subgroup analysis of the impact of the glycoprotein IIb/IIIa inhibitor abciximab in patients undergoing elective stent placement >2 hours after treatment with a 600 milligram loading dose of clopidogrel: Results from the ISAR REACT trial (2004) (0)
14 Antithrombotic therapy with or without aspirin after percutaneous coronary intervention or acute coronary syndrome in patients taking oral anticoagulation: a meta-analysis and network analysis of randomised controlled trials (2020) (0)
TCT-760 Predictors of Elevated Tumor Marker Carbohydrate Antigen 125 in Patients Undergoing Transcatheter Aortic Valve Implantation. (2016) (0)
Diversity of expertise in a united cardiology specialty (2019) (0)
Time-of-day at symptom onset was not associated with infarct size and long-term prognosis in patients with ST-segment elevation myocardial infarction (2019) (0)
Risk for procedural failure of coronary stent placement (1998) (0)
TCT-840 Clinical outcomes of patients treated with Nobori biolimus-eluting stent: meta-analysis of randomized trials (2013) (0)
AS-095 Differential Vascular Healing Patterns with Rapid Absorption Biodegradable Polymer Sirolimus-Eluting Stents versus Durable Polymer Everolimus-Eluting Stents (2012) (0)
Results Histological Data After Stent Implantation in Atherosclerotic Rabbits and Correlation to OCT (2013) (0)
TCT-295 Differential Prognostic Value of Galectin-3 According to Levels of Carbohydrate Antigen 125 in Transcatheter Aortic Valve Implantation (2018) (0)
A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions: study design and protocol. (2010) (0)
Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes (2021) (0)
Stent or percutaneous transluminal coronary angioplasty for occluded coronary arteries in patients with acute myocardial infarction ineligible for thrombolysis (STOPAMI-3) trial (2003) (0)
Current and Future Perspectives for Drug-eluting Stents (2006) (0)
Drug-Eluting Stents and In-Stent Restenosis—Reply (2005) (0)
Reply: Baseline or Post-Procedural High-Sensitivity Troponin? Probably Both. (2017) (0)
Optimal periprocedural antithrombotic therapy in percutaneous coronary intervention: Between a rock and a hard place? (2016) (0)
Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes. (2021) (0)
Commentary: Ticagrelor monotherapy—Not for CABG? (2022) (0)
Evaluation of a Low-Dose Radiation During Transcatheter Aortic Valve Implantation. (2020) (0)
The National Institutes of Health. We Thank Haleh Nadim and Sarah Pihonak for Excellent Technical Help and Elaine Lavelle for Assistance with Data Management. Fetal Nucleated Erythrocytes in Maternal Circulation Do Not Display a Classic Membrane-associated Apopto- Tic Characteristic (phosphatidylser (2003) (0)
[New intervention procedures: lasers, atherectomy, stents]. (1993) (0)
Obesity-associated hypertension is ameliorated in patients with TLR4 single nucleotide polymorphism (SNP) rs4986790 (2015) (0)
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of glassy and twilight. (2023) (0)
Sex Differences in 10-Year Outcomes After Percutaneous Coronary Intervention With Drug-Eluting Stents: Insights From the DECADE Cooperation (2023) (0)
High-sensitivity cardiac troponin T in patients with ST-segment elevation myocardial infarction. (2019) (0)
The Effect of a Prasugrel- versus a Ticagrelor-based Strategy on Total Ischemic and Bleeding Events in Patients with Acute Coronary Syndromes. (2022) (0)
The role of bivalirudin in percutaneous coronary intervention (2018) (0)
TCT-783 Comparison of Carbohydrate Antigen 125 and N-terminal Pro-Brain Natriuretic Peptide for Risk Prediction after Transcatheter Aortic Valve Implantation (2017) (0)
Prospective randomized trial of antiplatelet vs. anticoagulation treatment after intracoronary Palmaz-Schatz stent placement-6-month follow-up (1996) (0)
The editor's roundtable: bare-metal stents versus drug-eluting stents-indications and complications. (2008) (0)
Comments on the 2018 ESC / EACTS Guidelines onMyocardial Revascularization (0)
Abstract 18483: Randomized, Double Blind Trial of Tapered versus Abrupt Interruption of Long Term Clopidogrel Therapy After Drug-Eluting Stent Implantation - ISAR-CAUTION (2013) (0)
Influence of marital status in patients undergoing transcatheter aortic valve implantation. (2019) (0)
Association of plasma amyloid-beta (1-40) levels with incident coronary artery disease and cardiovascular mortality (2013) (0)
Ticagrelor or Prasugrel in Acute Coronary Syndromes. Reply. (2020) (0)
In the bivalirudin era, are we still looking for a potent antiplatelet agent? (2012) (0)
Outcomes after complete dissolution of everolimus-eluting bioresorbable scaffolds implanted during routine practice. (2020) (0)
TCT-101 Prognostic role of restenosis in 10,004 patients undergoing routine control angiography after coronary stenting (2014) (0)
CLINICAL RESEARCH Acute Coronary Syndromes Gender and Myocardial Salvage After Reperfusion Treatment in Acute Myocardial Infarction (2005) (0)
Abstract 3684: Reduced Expression of Adhesion Receptors CXCR4, LFA-1 and VLA-4 on G-CSF-mobilized CD34+ Progenitor Cells in Acute Myocardial Infarction (2006) (0)
De Ritis ratio and long‐term major cardiovascular adverse events in patients undergoing elective percutaneous coronary intervention (2022) (0)
Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes (2021) (0)
TCT-647 Hemodynamic valve deterioration following transcatheter aortic valve implantation: prevalence and predictors of elevated transvalvular gradients (2018) (0)
Reply: Duration of Triple Therapy: A Clinical Question Yet to Be Answered. (2015) (0)
Predictors for long-term survival after transcatheter edge-to-edge mitral valve repair (2016) (0)
CD4+ lymphocyte count predicts recurrent thrombotic events in HIV-infected patients with acute coronary syndromes (2013) (0)
CLINICAL RESEARCH Interventional Cardiology Influence of Treatment Duration With a 600-mg Dose of Clopidogrel Before Percutaneous Coronary Revascularization (2004) (0)
, Melchior Placement Previous Cytomegalovirus Infection and Risk of Coronary Thrombotic Events After Stent (1999) (0)
Association between duration of drug-coated balloon inflation and efficacy in patients with drug-eluting stent restenosis (2021) (0)
Abstract 12760: Identification of a Novel Susceptibility Locus on Chromosome 12 With the First Genome-Wide Association Study on Coronary Restenosis (2011) (0)
TCT-692 Unilateral carotid artery occlusion is associated with higher stroke rate after TAVI. (2016) (0)
1025-42 Abciximab administration for the prevention of angiographic restenosis in small coronary arteries: Results from the randomized ISAR-SMART-2 trial (2004) (0)
Sex-specific Inequalities in the Treatment of Severely Calcified Coronary Lesions: A Sub-analysis of the PREPARE-CALC Trial (2023) (0)
Randomized comparison between bare-metal stent plus colchicine versus drug-eluting stent alone in prevention of clinical adverse events after percutaneous coronary intervention. (2020) (0)
11 Ten-year clinical outcomes from a randomized trial of polymer-free versus durable polymer drug-eluting stents ten-year results of the intracoronary stenting and angiographic results: test efficacy of sirolimus- and probucol- and zotarolimus- eluting stents (ISAR-test 5) trial (2020) (0)
27 Angiographic restenosis after coronary stenting in patients with previous coronary bypass surgery (2017) (0)
Circulation: Cardiovascular Interventions (2022) (0)
OP-EHEA180727 167..176 (2019) (0)
Abstract 3244: Abciximab Effect on Clinical and Angiographic Restenosis in High-Risk Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Results of the ISAR-REACT 2 Trial (2006) (0)
Erratum to: Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with Diabetes mellitus: a patient-level meta-analysis of randomized trials (2011) (0)
ANTIPLATELET ACTION OF CLOPIDOGREL AND PRASUGREL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION COMPLICATED BY CARDIOGENIC SHOCK (2013) (0)
Percutaneous Coronary Intervention in Acute ST Segment Elevation Myocardial Infarction (2012) (0)
Antithrombotic drugs: thrombin inhibitors and thrombin generation inhibitors (2008) (0)
TCT-419 Long-term clinical outcomes of patients presenting with in-stent restenosis after drug-eluting stent implantation for unprotected left main coronary artery. A pooled analysis of the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 randomized trials (2017) (0)
TCT-97 Subintimal Versus Intraplaque Recanalization of Coronary Chronic Total Occlusions Mid-Term Angiographic and Optical Coherence Tomography Findings from the ISAR-OCT-CTO Registry (2019) (0)
Alkaline Phosphatase and Prognosis in Patients with Diabetes Mellitus and Ischemic Heart Disease. (2022) (0)
LONG–TERM OUTCOMES OF BIODEGRADABLE STENTS IN DIABETES: UPDATED POOLED ANALYSIS OF OUTCOMES VERSUS DURABLE POLYMER SIROLIMUS–ELUTING STENTS (2013) (0)
P4707Incidence and outcome of endovascular therapy in subclavian occlusive disease involving the vertebral artery origin (2019) (0)
Abstract 2531: Sirolimus-Eluting Stents Compared to Bare Metal Stents in Patients with Diabetes Mellitus: Patient-Level Meta-Analysis of Randomized Trials (2008) (0)
No-reflow after percutaneous coronary intervention: a correlate of poor outcome in both persistent and transient forms. (2018) (0)
Does Size Matter?: In Search of a Physiological Definition of Myocardial Atrophy (2017) (0)
SEX-RELATED EFFECTIVENESS OF BIVALIRUDIN VERSUS ABCIXIMAB AND HEPARIN IN NSTEMI: LESSONS FROM THE INTRACORONARY STENTING AND ANTITHROMBOTIC REGIME: RAPID EARLY ACTION FOR CORONARY TREATMENT (ISAR-REACT-4) TRIAL (2013) (0)
P1590Percutaneous systemic av-valve repair for the treatment of severe tricuspid regurgitation in patients with congenitally corrected transposition of the great arteries (2018) (0)
Szintigraphically assessed myocardial salvage in patients with acute myocardial infarction undergoing stent supported angioplasty (1999) (0)
Reply: Prasugrel Versus Ticagrelor in Non-ST-Segment-Elevation Acute Coronary Syndrome. (2021) (0)
Stent Thrombosis in Patients Treated for Acute or Chronic Coronary Syndrome. (2021) (0)
Assessment of stent optimization in clinical practice using optical coherence tomography: a multicentric observational study (2021) (0)
No Matter How Slowly You Go as Long as You Do Not Stop. (2022) (0)
Stenting for Small Coronary Vessels : A (2016) (0)
Changes in high-sensitivity troponin according to optical characteristics of neointima and treatment modality of in-stent restenosis (2022) (0)
A case where the principle of "one question, one answer" may work better. (2012) (0)
Abstract 3342: Adequacy of Inclusion of Post-Procedural Bleeding in a Composite End Point for Assessment of Outcome After Percutaneous Coronary Intervention. (2007) (0)
Antithrombotic drugs: intravenous antiplatelet drugs (2008) (0)
IMPACT OF CALCIUM CHANNEL BLOCKERS ON THE PHARMACODYNAMIC EFFECT AND THE CLINICAL EFFICACY OF CLOPIDOGREL AFTER DRUG ELUTING STENTING (2011) (0)
TCT-711 Prevalence and Clinical Impact of Bioprosthesis Thrombosis After Transcatheter Aortic Valve Implantation. A Collaborative Meta-Analysis (2019) (0)
TCT-693 Impact of the syntax score on the outcome of the left main after drug-eluting stent implantation (2012) (0)
Polymer-Free Drug-Eluting Stents – an inVEST ( A ) ment for the Future ? (2009) (0)
Good medicines for bad genes. (2001) (0)
Sirolimus-eluting vs. paclitaxel-eluting stents in diabetic and non-diabetic patients with in "LIMUS"-stent restennosis, results from the ISAR DESIRE 2 trial (2013) (0)
TCT-13 Ticagrelor Monotherapy in Patients With Peripheral Artery Disease Undergoing PCI (2022) (0)
P2273Qualitative and quantitative neointimal characterization by optical coherence tomography in patients presenting with in-stent restenosis (2018) (0)
Interferon gamma receptor 1 88 G/A polymorphism and restenosis following coronary artery stenting (2003) (0)
Abstract 1898: Risk Variants Identified in Genome-wide Association Studies and Their Role in Myocardial Infarction (2009) (0)
P529Angiographic restenosis after coronary stenting in patients with previous coronary bypass surgery (2017) (0)
EXTENT OF ATHEROSCLEROSIS IRRESPECTIVE OF STENOSIS IS A BETTER OUTCOME PREDICTOR THAN NUMBER OF OBSTRUCTED VESSELS IN INVASIVE CORONARY ANGIOGRAPHY (2011) (0)
Clinical practice guidelines of the ESC on myocardial revascularization, 2014 (2015) (0)
Prevalence and patterns of in-stent neoatherosclerosis in lower extremity artery disease. (2023) (0)
High Sensitivity Cardiac Troponin T in Patients with Severe Chronic Kidney Disease and suspected Acute Coronary Syndrome (2021) (0)
Abstract 12474: Amyloid-{beta} 1-40 as an Independent Cardiovascular Risk Factor: First Evidence in Patients With Cardiovascular Disease (2013) (0)
P4471The 4q32.1 coronary artery disease locus influences disease risk via differential transcription factor binding (2017) (0)
Access route and clinical outcomes after ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing invasive treatment strategy. (2022) (0)
TCT-841 ORAl iMmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: a patient-level meta-analysis of randomized trials (2013) (0)
TCT-661 Angiographic Results of Everolimus-Eluting Stents for the Treatment of In-Stent Restenosis (2019) (0)
PIA polymorphism and myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis (2003) (0)
1022-85 Glucose-insulin-potassium infusion improves myocardial salvage in diabetic patients with acute myocardial infarction treated with reperfusion therapy (2004) (0)
Derivation and validation of the ISAR score to predict the risk of repeat percutaneous coronary intervention for recurrent drug-eluting stent restenosis. (2023) (0)
Age dependent impact of the 894 TT genotype of the endothelial nitric oxide synthase on the outcome in men following coronary stent placement (2002) (0)
Apolipoprotein E genotype predicts the outcome after coronary artery stenting (2002) (0)
irolimus and Paclitaxel n Polymer-Based Drug-Eluting Stents imilar But Different (2016) (0)
Peroxisome proliferator-activated receptor γ gene polymorphisms and restenosis in diabetic patients after stenting in coronary arteries (2004) (0)
Individaulizable drug-eluting stent system to abgrogate restenosis (ISAR): Preclinical results on feasibility, safety and efficacy of a novel drug-eluting stent system that uses on-site polymer-free rapamycin coating (2004) (0)
TCT-353 Long-Term Outcomes of Biodegradable Polymer Drug-Eluting Stents versus Durable Polymer Sirolimus-Eluting Stents in Patients with Diabetes: A Pooled Analysis of Individual Patient Data from the ISAR-TEST 4 and LEADERS Randomized Trials (2012) (0)
High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry. (2023) (0)
TCT-740 Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials (2012) (0)
Acute coronary syndromes Prasugrel plus bivalirudin vs . clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction (0)
Small Coronary Vessel Size: A Great Need for a Standardized Definition (2022) (0)
Ten-Year Clinical Outcomes in Patients With Acute Coronary Syndrome Treated With Biodegradable, Permanent-Polymer or Polymer-Free Drug-Eluting Stents. (2022) (0)
FINAL FIVE-YEAR FOLLOW-UP OF POLYMER-FREE SIROLIMUS- AND PROBUCOL-ELUTING STENTS VERSUS NEW GENERATION ZOTAROLIMUS-ELUTING STENTS IN PATIENTS WITH CORONARY ARTERY DISEASE (2015) (0)
Combined rotational atherectomy and cutting balloon angioplasty prior to drug‐eluting stent implantation in severely calcified coronary lesions: The PREPARE‐CALC‐COMBO study (2022) (0)
The influence of pacing rate and autonomic blockade on human primary and secondary atrial pacemakers. (1998) (0)
network meta-analysis with and without diabetes: collaborative Drug eluting and bare metal stents in people (2008) (0)
1121-50 Peroxisome proliferator-activated receptor gamma gene polymorphisms and risk of restenosis after coronary artery stenting in patients with diabetes (2004) (0)
Vessel size, stent strut thickness, and restenosis after coronary stent placement: A subgroup analysis of the randomized ISAR-STEREO-2 trial (2003) (0)
P4500Prognostic value of galectin-3 according to carbohydrate antigen 125 in transcatheter aortic valve implantation (2018) (0)
Abstract 2810: Impact of Diabetes Mellitus on Clinical and Angiographic Outcomes in the Drug Eluting Stent Era (2006) (0)
Histopathology-Based Deep-Learning Predicts Atherosclerotic Lesions in Intravascular Imaging (2021) (0)
Association of the apolipoprotein(a) genomic region with myocardial infarction (2011) (0)
Machine Learning Identifies New Predictors on Restenosis Risk after Coronary Artery Stenting in 10,004 Patients with Surveillance Angiography (2023) (0)
Risk of stent thrombosis with bioresorbable vascular scaffolds – Authors' reply (2016) (0)
RANDOMIZED TRIAL OF A POLYMER-FREE DUAL DRUG-ELUTING STENT VERSUS POLYMER-BASED DRUG-ELUTING STENTS - TWO-YEAR CLINICAL AND ANGIOGRAPHIC OUTCOMES (2010) (0)
Drug-Eluting Stent Safety -- Is it Time to Turn the Page on Barcelona 2006? (2009) (0)
P715Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic stroke - a meta-analysis of randomized clinical trials (2018) (0)
Abstract 3054: Comparison of Overlapping Non-Polymer versus Polymer-Based DES: Finding a Better Balance Between Neointimal Suppression and Arterial Healing (2006) (0)
Impact of different antiplatelet therapy cessation modes on outcomes in patients treated with ticagrelor with or without aspirin after PCI: the twilight-antiplatelet cessation study (2022) (0)
Significant aortic regurgitation after transfemoral aortic valve implantation: patients' gender as independent risk factor. (2015) (0)
TCT-713 Hemodynamic Valve Dysfunction Following Transcatheter Aortic Valve Implantation: Prevalence and Predictors of Elevated Transvalvular Gradients (2018) (0)
TCT-50 Influence of Age on Clinical Outcomes in Patients with NSTEMI Undergoing Treatment with Abciximab plus Unfractionated Heparin vs. Bivalirudin: Analysis of the ISAR React 4 Study (2012) (0)
Immature Platelet Fraction Predicts Adverse Events in Patients With Acute Coronary Syndrome: the ISAR-REACT 5 Reticulated Platelet Substudy (2022) (0)
Impact of angiographic restenosis detected by routine angiographic follow-up at six months on long-term mortality (2002) (0)
TCT-382 Optical Coherence Tomography–Based Characterization of Neointimal Atherosclerotic Changes in Patients Presenting With Very Late Stent Thrombosis or In-Stent Restenosis (2021) (0)
TCT-506 An updated meta-analysis of randomized trials comparing complete versus culprit-only revascularization in patients undergoing primary percutaneous coronary intervention (2017) (0)
Rapid and Short Communication (2004) (0)
30 day outcome after early discharge in low risk ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention (2023) (0)
Obesity and a history of low response to clopidogrel treatment are predictors for a reduced antiplatelet action of prasugrel treatment (2013) (0)
9 Target vessel and non-target vessel related events at 10 years post percutaneous coronary intervention (2021) (0)
P ost Analysis From Two Randomized Trials of irolimus-Eluting Stents Versus Paclitaxel-Eluting tents in High-Risk Patients With Coronary Artery Disease (2006) (0)
[Recanalization of chronic total coronary occlusion: indications and results]. (2010) (0)
Antithrombotic drugs: fibrinolytic therapy (2008) (0)
Therapeutic window for P2Y12-Receptor inhibition: a collaborative analysis of the relation between platelet reactivity, stent thrombosis and bleeding (2015) (0)
coronary artery stenting in patients with the DD genotype of the ACE gene Angiotensin I-converting enzyme (ACE) inhibitors and restenosis after (2011) (0)
[Errors and difficulties in the diagnosis and management of acute and chronic abdomen in children]. (2002) (0)
Intrapatient dependence of restenosis between lesions treated with intracoronary stenting (1998) (0)
TCT-48 Two Year Follow-Up And Sub-group Analysis Of A Polymer-Free Sirolimus- And Probucol-Eluting Stent vs. A New Generation Zotarolimus-Eluting Stent In Coronary Artery Disease (2012) (0)
Wednesday, 29 August 2012 (2012) (0)
P4680Comparative prognostic value of postprocedural CK-MB and high-sensitivity troponin T in patients with non-ST-segment elevation myocardial infarction undergoing PCI (2017) (0)
Prognostic impact of restoration of the reperfusion at the epicardial artery and tissue levels in patients with acute myocardial infarction (2010) (0)
TCT-714 Incidental findings in Multislice CT for procedural planning in transcatheter aortic valve implantation: prevalence, clinical relevance and outcome. (2016) (0)
Abstract 5216: The Effect of Erythropoietin on Restenosis in Patients With Acute Myocardial Infarction Undergoing PCI (2009) (0)
TCT-577 Early- Versus New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: Results froma Patient-Level Pooled Analysis of Randomized Controlled Trials (2015) (0)
How should we treat "undilatable" coronary stents?: Treating "undilatable" coronary stents. (2022) (0)
[Bowel intussusception on the child: clinical therapeutical study]. (2003) (0)
Oral Presentation No. 64 Elevated soluble glycoprotein VI, a specific predictor of bleeding risk in patients with chronic coronary syndromes undergoing percutaneous coronary intervention (2022) (0)
Images in cardiology: Structural failure of a coronary stent. (2001) (0)
Reteplase in acute myocardial infarction. Authors' reply (2004) (0)
TCT-156 Outcomes After Transcatheter Aortic Valve Implantation Using a Novel Balloon-Expandable Transcatheter Heart Valve: A Single Center Experience (2015) (0)
RANDOMIZED CLINICAL TRIAL TO COMPARE THE NEPHROTOXIC EFFECTS OF ISO-OSMOLAR VS. LOW-OSMOLAR CONTRAST MEDIUM IN DIABETIC PATIENTS WITH REDUCED RENAL FUNCTION (2010) (0)
Basic concepts of atherothrombosis (2008) (0)
Comparison of Vascular Closure Devices vs Manual Compression After Femoral Artery Puncture in Patients on Oral Anticoagulation - Post Hoc Analysis of the ISAR-CLOSURE Trial. (2021) (0)
Prognostic value of N-terminal-pro brain natriuretic peptide - Comparison of patients with diastolic and systolic heart failure (2004) (0)
Is it naive to load only clopidogrel-naive patients prior to PCI? (2010) (0)
Is there a role for oral rapamycin in restenosis prevention after bare-metal stent implantation? (2006) (0)
[A friend in need is a friend indeed: the case of drug-eluting stents, diabetes and small vessel size]. (2006) (0)
FIVE-YEAR CLINICAL OUTCOMES OF SIROLIMUS-ELUTING VERSUS PACLITAXEL-ELUTING STENTS IN HIGH RISK PATIENT SUBSETS: A POOLED ANALYSIS OF 3 RANDOMIZED TRIALS (2010) (0)
Reteplase in Acute Myocardial Infarction—Reply (2004) (0)
COMPARISON OF NEXT GENERATION P2Y12 INHIBITORS TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME: AN ANALYSIS FROM THE BRITISH CARDIOVASCULAR INTERVENTION SOCIETY DATABASE OF 382,361 ‘REAL-WORLD’ PATIENTS (2021) (0)
Bioresorbable vascular scaffolds for complex coronary anatomies: "Icarus' flight" for interventional cardiologists? (2017) (0)
Subject Index Vol. 111, 2008 (2008) (0)
TCT-373 Temporal course of neointimal maturity after implantation of biodegradable polymer sirolimus-eluting stents as assessed by optical coherence tomography gray-scale signal intensity at 3, 6 and 9 months (2014) (0)
Letter by Kessler et al Regarding Article, "Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials". (2021) (0)
Bivalirudin in patients with ST-segment elevation myocardial infarction (2022) (0)
Acute Coronary Syndromes ender and Myocardial Salvage After eperfusion Treatment in Acute Myocardial Infarction (2016) (0)
provided with a rough surface stent and its manufacturing method (2002) (0)
DIFFERENTIAL VASCULAR HEALING PATTERNS WITH RAPID ABSORPTION BIODEGRADABLE POLYMER SIROLIMUS-ELUTING STENTS VERSUS DURABLE POLYMER EVEROLIMUS-ELUTING STENTS (2012) (0)
Frequency of subclavian artery stenosis in patients with mammarian artery coronary bypass and suspected coronary artery disease progression. (2022) (0)
Adverse events with bioresorbable vascular scaffolds in routine percutaneous coronary interventions: "coup de théâtre" or unfinished play? (2017) (0)
Response to Letter Regarding Article, “Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention” (2012) (0)
Drug-eluting stents for drug-eluting stent restenosis: stick with the old or switch to a new one? (2014) (0)
Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes (2022) (0)
Drug-eluting stent for revascularization of infrapopliteal arteries: a meta-analysis of randomized trials (2013) (0)
Outcome with early invasive versus conservative approach in patients over 75 years of age with non-ST-segment elevation myocardial infarction (2023) (0)
Iliofemoral artery predilation prior to transfemoral transcatheter aortic valve implantation in patients with aortic valve stenosis and advanced peripheral artery disease (2023) (0)
Long-term outcome after coronary stenting Adnan Kastrati , Donald Hall and Albert Schömig (2016) (0)
Subject Index Vol. 112, 2009 (2008) (0)
TCT-295 Neointimal growth patterns after between biodegradable polymer biolimus-eluting or permanent polymer everolimus-eluting stent implantation assessed with newly developed “spread-out neointimal topography”: Results from ISAR-TEST6 OCT trial (2012) (0)
Contents Vol. 112, 2009 (2008) (0)
Percutaneous Coronary Interventional Strategies for the Treatment of Coronary In-Stent Restenosis : Systematic Review and Network Meta-analysis (2014) (0)
MULTICENTER EVALUATION OF THE ACURATE NEO TRANSFEMORAL TRANSCATHETER HEART VALVE – CLINICAL RESULTS AND PROPENSITY MATCHED COMPARISON WITH SAPIEN 3 (2017) (0)
CorrespondenceLetter to the EditorReply (2009) (0)
P3174Neoatherosclerosis in patients with coronary stent thrombosis: findings from optical coherence tomography imaging (2018) (0)
2201Comparative efficacy and safety of novel biodegradable polymer sirolimus-eluting stents versus permanent polymer everolimus-eluting stents at 5-year follow-up (2017) (0)
TCT-560 Paclitaxel-Eluting Balloon versus conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery. The ISAR-PEBIS randomized trial (2017) (0)
Investigator-driven randomized trials (2017) (0)
Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention. (2016) (0)
1121-49 Homocysteine levels and methylenetetrahydrofolate reductase polymorphisms are not associated with restenosis after coronary artery stenting (2004) (0)
Abstract 4308: Clopidogrel Response Status Assessed With Multiplate Point-of-Care Analysis and the Incidence and Timing of Stent Thrombosis Over 6 Months Following Coronary Stenting (2009) (0)
Evaluation of the BiodivYsio Stent with matrix HI coating designed for local drug delivery in coronary Arteries: A randomized trial (2003) (0)
The influence of lipoprotein (a) levels on angiographic and clinical outcome after coronary artery stent placement (1998) (0)
Creatine kinase and bleeding in patients with acute coronary syndromes (2021) (0)
TCT-471 Impact of New- versus Early-Generation Drug Eluting Stents in Women according to Age: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. (2016) (0)
A prospective trial of a novel low‐dose paclitaxel‐coated balloon therapy in patients with restenosis in drug‐eluting coronary stents Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In‐stent REstenosis 3A (ISAR‐DESIRE 3A) (2021) (0)
TCT-596 Iliofemoral Artery Predilation Prior to Transfemoral Transcatheter Aortic Valve Implantation in Patients With Aortic Valve Stenosis and Advanced Peripheral Artery Disease (2022) (0)
P2632Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Adnan Kastrati?

Adnan Kastrati is affiliated with the following schools:

KU Leuven
Columbia University
Technical University of Munich
Kyoto University